


(19) **United States**(12) **Patent Application Publication** (10) **Pub. No.: US 2020/0168798 A1****HAN et al.**(43) **Pub. Date: May 28, 2020**(54) **ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME**

(2013.01); C09K 2211/1029 (2013.01); C09K 2211/1059 (2013.01); H01L 51/0087 (2013.01)

(71) Applicant: **Samsung Display Co., Ltd.**, Yongin-si (KR)(72) Inventors: **Junghoon HAN**, Yongin-si (KR); **Soobyung KO**, Yongin-si (KR); **Sungbum KIM**, Yongin-si (KR); **Sujin SHIN**, Yongin-si (KR); **Eunsoo AHN**, Yongin-si (KR); **Jaesung LEE**, Yongin-si (KR); **Mina JEON**, Yongin-si (KR); **Youngkook KIM**, Yongin-si (KR)(21) Appl. No.: **16/532,426**(22) Filed: **Aug. 5, 2019**(30) **Foreign Application Priority Data**

Nov. 23, 2018 (KR) 10-2018-0146771

Publication Classification(51) **Int. Cl.****H01L 51/00** (2006.01)**C09K 11/06** (2006.01)**C07F 15/00** (2006.01)(52) **U.S. Cl.**CPC **H01L 51/009** (2013.01); **C09K 11/06**(2013.01); **C07F 15/0086** (2013.01); **H01L****51/008** (2013.01); **H01L 51/5088** (2013.01);**C09K 2211/185** (2013.01); **C09K 2211/1044**(57) **ABSTRACT**An organic light-emitting device includes an organometallic compound represented by $M_1(L_1)_{n1}(L_2)_{m2}$, wherein L_1 is a ligand represented by Formula 1-1:

In Formula 1-1, *1 to *4 indicate a binding site to M_1 , and Z_{11} and Z_{12} are respectively boron (B) and nitrogen (N), or N and B. When M_1 binds to an α -position of the B or N atom, metal-ligand charge transfer in the complex may be improved. An OLED including the organometallic compound may have a long lifespan and improved luminescent efficiency and colorimetric purity.



190
150
110

FIG. 1




FIG. 2




FIG. 3





FIG. 4



**ORGANOMETALLIC COMPOUND AND
ORGANIC LIGHT-EMITTING DEVICE
INCLUDING THE SAME**

CROSS-REFERENCE TO RELATED
APPLICATION

[0001] This application claims priority to and the benefit of Korean Patent Application No. 10-2018-0146771, filed on Nov. 23, 2018, in the Korean Intellectual Property Office, the entire content of which is incorporated herein by reference.

BACKGROUND

1. Field

[0002] One or more aspects of example embodiments of the present disclosure relate to an organometallic compound and an organic light-emitting device including the same.

2. Description of the Related Art

[0003] Organic light-emitting devices (OLEDs) are self-emitting devices that may have wide viewing angles, high contrast ratios, and/or short response times. In addition, OLEDs may exhibit high luminance, driving voltage, and/or response speed characteristics, and may produce full-color images.

[0004] An example OLED includes a first electrode on a substrate, and may include a hole transport region, an emission layer, an electron transport region, and a second electrode sequentially stacked on the first electrode. Holes provided by the first electrode may move toward the emission layer through the hole transport region, and electrons provided by the second electrode may move toward the emission layer through the electron transport region. Carriers (such as holes and electrons) may recombine in the emission layer to produce excitons. These excitons may transition from an excited state to the ground state to thereby generate light.

SUMMARY

[0005] One or more aspects of example embodiments of the present disclosure are directed toward an organometallic compound and an organic light-emitting device including the same.


[0006] Additional aspects will be set forth in part in the description which follows and, in part, will be apparent from the description, or may be learned by practice of the presented embodiments.

[0007] One or more example embodiments of the present disclosure provide an organometallic compound represented by Formula 1:

$M_1(L_1)_{n1}(L_2)_{n2}$,

Formula 1

Formula 1-1



[0008] wherein, in Formulae 1 and 1-1,

[0009] M_1 may be selected from a first-row transition metal, a second-row transition metal, and a third-row transition metal,

[0010] L_1 may be a ligand represented by Formula 1-1,

[0011] L_2 may be selected from a monodentate ligand and a bidentate ligand,

[0012] n_1 may be 1,

[0013] n_2 may be selected from 0, 1, and 2,

[0014] A_{11} to A_{16} may each independently be selected from a C_5 - C_{60} carbocyclic group and a C_1 - C_{60} heterocyclic group,

[0015] X_{11} to X_{18} may each independently be selected from nitrogen (N) and carbon (C),

[0016] Y_{11} to Y_{14} may each independently be selected from N, C, oxygen (O), and sulfur (S),

[0017] i) Z_{11} may be boron (B), and Z_{12} may be N; or ii) Z_{11} may be N, and Z_{12} may be B,

[0018] T_{11} to T_{14} may each independently be selected from a single bond, $*-O-*$, $*-S-*$, $*-N(R_{17})-*$, and $*-C(R_{17})(R_{18})-*$,

[0019] L_{11} to L_{13} may each independently be selected from a single bond, $*-O-*$, $*-S-*$, $*-C(R_{19})(R_{20})-*$, $*-C(R_{19})=*$, $*-C(R_{19})-*$, $*-C(R_{19})=C(R_{20})-*$, $*-C(=O)-*$, $*-C(=S)-*$, $*-C\equiv C-*$, $*-B(R_{19})-*$, $*-N(R_{19})-*$, $*-P(R_{19})-*$, $*-Si(R_{19})(R_{20})-*$, $*-P(R_{19})(R_{20})-*$, and $*-Ge(R_{19})(R_{20})-*$,

[0020] a_{11} to a_{13} may each independently be selected from 0, 1, 2, and 3, provided that at least two selected from a_{11} to a_{13} are selected from 1, 2, and 3,

[0021] when a_{11} is 0, A_{11} and A_{13} may not be linked to each other; when a_{12} is 0, A_{12} and A_{14} may not be linked to each other; and when a_{13} is 0, A_{11} and A_{12} may not be linked to each other,

[0022] R_{11} to R_{20} may each independently be selected from hydrogen, deuterium, $-F$, $-Cl$, $-Br$, $-I$, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazino group, a hydrazono group, a substituted or unsubstituted C_1 - C_{60} alkyl group, a substituted or unsubstituted C_2 - C_{60} alkenyl group, a substituted or unsubstituted C_2 - C_{60} alkynyl group, a substituted or unsubstituted C_1 - C_{60} alkoxy group, a substituted or unsubstituted C_3 - C_{10} cycloalkyl group, a substituted or unsubstituted C_1 - C_{10} heterocyc-

cloalkyl group, a substituted or unsubstituted C₃-C₁₀ cycloalkenyl group, a substituted or unsubstituted C₁-C₁₀ heterocycloalkenyl group, a substituted or unsubstituted C₆-C₆₀ aryl group, a substituted or unsubstituted C₆-C₆₀ aryloxy group, a substituted or unsubstituted C₆-C₆₀ arylthio group, a substituted or unsubstituted C₁-C₆₀ heteroaryl group, a substituted or unsubstituted C₁-C₆₀ heteroaryloxy group, a substituted or unsubstituted C₁-C₆₀ heteroarylthio group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group, —Si(Q₁)(Q₂)(Q₃), —B(Q₁)(Q₂), —N(Q₁)(Q₂), —P(Q₁)(Q₂), —C(=O)(Q₁), —S(=O)(Q₁), —S(=O)₂(Q₁), —P(=O)(Q₁)(Q₂), and —P(=S)(Q₁)(Q₂),

[0023] at least two adjacent groups selected from R₁₁ to R₂₀ may optionally be bound to form a substituted or unsubstituted C₅-C₆₀ carbocyclic group or a substituted or unsubstituted C₁-C₆₀ heterocyclic group,

[0024] b11 to b16 may each independently be selected from 1, 2, 3, 4, 5, 6, 7, and 8,

[0025] Q₁ to Q₃ may each independently be selected from hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazino group, a hydrazonyl group, a C₁-C₆₀ alkyl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, a C₁-C₆₀ alkoxy group, a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₁-C₆₀ heteroaryl group, a C₁-C₆₀ heteroaryloxy group, a C₁-C₆₀ heteroarylthio group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, a biphenyl group, and a terphenyl group,

[0026] *1 to *4 may each independently indicate a binding site to M₁, and

[0027] * and *' each indicate a binding site to an adjacent atom.

[0028] One or more example embodiments of the present disclosure provide an organic light-emitting device including: a first electrode; a second electrode; and an organic layer between the first electrode and the second electrode, wherein the organic layer may include an emission layer and the organometallic compound represented by Formula 1.

BRIEF DESCRIPTION OF THE DRAWINGS

[0029] These and/or other aspects of example embodiments of the present disclosure will become apparent and more readily appreciated from the following description, taken in conjunction with the accompanying drawings, in which:

[0030] FIG. 1 illustrates a schematic cross-sectional view of an organic light-emitting device according to embodiments of the present disclosure;

[0031] FIG. 2 illustrates a schematic cross-sectional view of an organic light-emitting device according to embodiments of the present disclosure;

[0032] FIG. 3 illustrates a schematic cross-sectional view of an organic light-emitting device according to embodiments of the present disclosure; and

[0033] FIG. 4 illustrates a schematic cross-sectional view of an organic light-emitting device according to embodiments of the present disclosure.

DETAILED DESCRIPTION

[0034] Reference will now be made in more detail to embodiments, examples of which are illustrated in the accompanying drawings, wherein like reference numerals refer to like elements throughout and duplicative descriptions thereof may not be provided. In this regard, the present embodiments may have different forms and should not be construed as being limited to the descriptions set forth herein. Accordingly, the embodiments are merely described below, by referring to the drawings, to explain aspects of the present description. As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items. Expressions such as “at least one of”, “one of”, and “selected from”, when preceding a list of elements, modify the entire list of elements and do not modify the individual elements of the list. Further, the use of “may” when describing embodiments of the present disclosure refers to “one or more embodiments of the present disclosure.”

[0035] As the present disclosure allows for various changes and numerous embodiments, selected embodiments will be illustrated in the drawings and described in more detail in the written description. Effects, features, and methods of achieving the present disclosure will be obvious by referring to example embodiments of the present disclosure with reference to the attached drawings. The present disclosure may, however, be embodied in many different forms and should not be construed as being limited to the embodiments set forth herein.


[0036] In the embodiments described in the present specification, an expression used in the singular encompasses the expression of the plural and vice versa, unless explicitly stated, and/or the alternate form has a clearly different meaning in context.

[0037] In the present specification, it is to be understood that terms such as “including,” “having,” and “comprising” are intended to indicate the existence of the features or components disclosed in the specification, and are not intended to preclude the possibility that one or more other features or components may exist and/or may be added.

[0038] It will be understood that when a layer, region, or component is referred to as being “on”, “over”, or “onto” another layer, region, or component, it may be directly or indirectly formed over the other layer, region, or component. In some embodiments, for example, intervening layers, regions, or components may be present. In contrast, when an element is referred to as being “directly on” another element, no intervening elements are present.

[0039] The sizes of components in the drawings (e.g., the thicknesses of layers, films, panels, regions, etc.) may be exaggerated for clarity and convenience of explanation. In other words, since sizes and thicknesses of components in the drawings are arbitrarily illustrated for convenience of explanation, the following embodiments are not limited thereto.

[0040] An organometallic compound may be represented by Formula 1:



Formula 1

[0041] wherein, in Formula 1, M₁ may be selected from a first-row transition metal, a second-row transition metal, and a third-row transition metal.


[0042] For example, in Formula 1, M₁ may be selected from platinum (Pt), palladium (Pd), copper (Cu), silver (Ag),

gold (Au), rhodium (Rh), iridium (Ir), ruthenium (Ru), osmium (Os), titanium (Ti), zirconium (Zr), hafnium (Hf), europium (Eu), terbium (Tb), and thulium (Tm), but embodiments of the present disclosure are not limited thereto.

[0043] In some embodiments, in Formula 1, M_1 may be selected from Pt, Pd, Cu, Ag, Au, Rh, Ir, Ru, and Os, but embodiments of the present disclosure are not limited thereto.

[0044] In some embodiments, in Formula 1, M_1 may be selected from Pt and Pd, but embodiments of the present disclosure are not limited thereto.

[0045] In Formula 1, L_1 may be a ligand represented by Formula 1-1:



Formula 1-1

[0046] In Formula 1-1, A_{11} to A_{16} may each independently be selected from a C_5 - C_{60} carbocyclic group and a C_1 - C_{60} heterocyclic group.

[0047] In some embodiments, in Formula 1-1, A_1 and A_{12} may each independently be selected from a C_5 - C_{60} carbocyclic group and a C_1 - C_{60} heterocyclic group, and


[0048] A_{13} to A_{16} may each independently be selected from a C_5 - C_{60} carbocyclic group, but embodiments of the present disclosure are not limited thereto.

[0049] In some embodiments, in Formula 1-1, A_1 to A_{16} may each independently be selected from a benzene group, a naphthalene group, an anthracene group, a phenanthrene group, a phenalene group, a triphenylene group, a pyrene group, a chrysene group, a cyclopentadiene group, a tetrahydronaphthalene group, a furan group, a thiophene group, a silole group, an indene group, a fluorene group, an indole group, a carbazole group, a benzofuran group, a dibenzofuran group, a benzothiophene group, a dibenzothiophene group, a benzosilole group, a dibenzosilole group, an indenopyridine group, an indolopyridine group, a benzofuopyridine group, a benzothienopyridine group, a benzosilolopyridine group, an indenopyrimidine group, an indolopyrimidine group, a benzofuopyrimidine group, a benzothienopyrimidine group, a benzosilolopyrimidine group, a dihydropyridine group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a quinoline group, an isoquinoline group, a quinoxaline group, a quinazoline group, a phenanthroline group, a benzoquinoline group, a benzoisoquinoline group, a benzo-


quinoxaline group, a benzoquinazoline group, a pyrrole group, a pyrazole group, an imidazole group, a dihydroimidazole group, a triazole group, a dihydrotriazole group, an oxazole group, an iso-oxazole group, a thiazole group, an isothiazole group, an oxadiazole group, a thiadiazole group, a benzopyrazole group, a benzimidazole group, a dihydrobenzimidazole group, an imidazopyridine group, a dihydroimidazopyridine group, an imidazopyrimidine group, a dihydroimidazopyrimidine group, an imidazopyrazine group, a dihydroimidazopyrazine group, a benzoxazole group, a benzothiazole group, a benzoxadiazole group, a benzothiadiazole group, a tetrahydroisoquinoline group, and a tetrahydroquinoline group, but embodiments of the present disclosure are not limited thereto.

[0050] In some embodiments, in Formula 1-1, A_{11} to A_{16} may each independently be selected from a benzene group, a naphthalene group, an indene group, a fluorene group, an indole group, a carbazole group, a benzofuran group, a dibenzofuran group, a benzothiophene group, a dibenzothiophene group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a quinoline group, an isoquinoline group, a quinoxaline group, a quinazoline group, a pyrazole group, an imidazole group, a dihydroimidazole group, a triazole group, a dihydrotriazole group, an oxazole group, an iso-oxazole group, a thiazole group, an isothiazole group, an oxadiazole group, a thiadiazole group, a benzopyrazole group, a benzimidazole group, a dihydrobenzimidazole group, a dihydroimidazopyridine group, a dihydroimidazopyrimidine group, a dihydroimidazopyrazine group, a benzoxazole group, and a benzothiazole group, but embodiments of the present disclosure are not limited thereto.


[0051] In some embodiments, in Formula 1-1, A_{11} to A_{16} may each independently be represented by one selected from Formulae 2-1 to 2-43, but embodiments of the present disclosure are not limited thereto:



2-1




2-2




2-3










-continued



-continued




-continued




-continued

2-24



2-33

2-25




2-34

2-26




2-35

2-27




2-36

2-28




2-37

2-29




2-38

2-30




2-39

2-31




2-40


2-32



2-41



2-42



2-43

[0052] In Formulae 2-1 to 2-43,

[0053] X₂₁ to X₂₃ may each independently be selected from C(R₂₄) and C—*, provided that at least two selected from X₂₁ to X₂₃ are each C—*,

[0054] X_{24} may be $N-^*$, and X_{25} and X_{26} may each independently be selected from $C(R_{24})$ and $C-^*$, provided that at least one selected from X_{25} and X_{26} is $C-^*$,

[0055] X_{27} and X_{28} may each independently be selected from O, S, $C(R_{24})$, N, $N(R_{25})$, and $N-^*$; and X_{29} may be selected from O, S, $C(R_{24})$, and $C-^*$, provided that i) at least one selected from X_{27} and X_{28} is $N-^*$, and X_{29} is $C-^*$, or ii) X_{27} and X_{28} are each $N-^*$, and X_{29} is selected from O, S, and $C(R_{24})$,

[0056] R_{21} to R_{24} may each independently be the same as R_{11} in Formula 1,

[0057] b21 may be selected from 1, 2, and 3,

[0058] b22 may be selected from 1, 2, 3, 4, and 5,

[0059] b23 may be selected from 1, 2, 3, and 4,

[0060] b24 may be selected from 1 and 2, and

[0061] * indicates a binding site to an adjacent atom.

[0062] In some embodiments, in Formula 1-1, A_1 and A_{12} may each independently be selected from an indole group, a carbazole group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a quinoline group, an isoquinoline group, a quinoxaline group, a quinazoline group, a pyrazole group, an imidazole group, a dihydroimidazole group, a triazole group, a dihydrotriazole group, an oxazole group, an iso-oxazole group, a thiazole group, an isothiazole group, an oxadiazole group, a thiadiazole group, a benzopyrazole group, a benzimidazole group, a dihydrobenzimidazole group, a dihydroimidazopyridine group, a dihydroimidazopyrimidine group, a dihydroimidazopyrazine group, a benzoxazole group, and a benzothiazole group, and

[0063] A_{13} to A_{16} may each independently be selected from a benzene group, a naphthalene group, an indene group, a fluorene group, a benzofuran group, a dibenzofuran group, a benzothiophene group, and a dibenzothiophene group, but embodiments of the present disclosure are not limited thereto.

[0064] In some embodiments, in Formula 1-1, A_{13} to A_{16} may each independently be a benzene group, but embodiments of the present disclosure are not limited thereto.

[0065] In Formula 1-1, X_{11} to X_{18} may each independently be selected from N and C.

[0066] In some embodiments, in Formula 1-1, X_{11} to X_{18} may each be C, but embodiments of the present disclosure are not limited thereto.

[0067] In Formula 1-1, Y_{11} to Y_{14} may each independently be selected from N, C, O, and S.

[0068] In some embodiments, in Formula 1-1, Y_{11} to Y_{14} may each independently be selected from N and C, but embodiments of the present disclosure are not limited thereto.

[0069] In some embodiments, in Formula 1-1, Y_{11} and Y_{12} may each be C, but embodiments of the present disclosure are not limited thereto.

[0070] In Formula 1-1, i) Z_{11} may be B, and Z_{12} may be N, or ii) Z_{11} may be N, and Z_{12} may be B. In Formula 1-1, T_{11} to T_{14} may each independently be selected from a single bond, $*-O-^*$, $*-S-^*$, $*-N(R_{17})-^*$, and $*-C(R_{17})(R_{18})-^*$. R_{17} and R_{18} are described below.

[0071] In some embodiments, in Formula 1-1, T_{11} to T_{14} may each be a single bond, but embodiments of the present disclosure are not limited thereto.

[0072] In Formula 1-1, L_{11} to L_{13} may each independently be selected from a single bond, $*-O-^*$, $*-S-^*$, $*-C(R_{19})(R_{20})-^*$, $*-C(R_{19})=^*$, $*=C(R_{19})-^*$, $*-C(R_{19})$

$=C(R_{20})-^*$, $*-C(=O)-^*$, $*-C(=S)-^*$, $*-C\equiv C-^*$, $*-B(R_{19})-^*$, $*-N(R_{19})-^*$, $*-P(R_{19})-^*$, $*-Si(R_{19})(R_{20})-^*$, $*-P(R_{19})(R_{20})-^*$, and $*-Ge(R_{19})(R_{20})-^*$. R_{19} and R_{20} are described below.

[0073] In some embodiments, in Formula 1-1, L_{11} to L_{13} may each be a single bond, but embodiments of the present disclosure are not limited thereto.

[0074] In Formula 1-1, a11 to a13 may respectively indicate the repeating number of $L_{11}(s)$ to $L_{13}(S)$. a11 to a13 may each independently be selected from 0, 1, 2, and 3, provided that at least two selected from a11 to a13 are selected from 1, 2, and 3. When any of a11 to a13 are 2 or greater, the at least two $L_{11}(s)$ to $L_{13}(S)$ may be identical to or different from each other. When a11 is 0, A_{11} and A_{13} may not be linked to each other. When a12 is 0, A_{12} and A_{14} may not be linked to each other. When a13 is 0, A_{11} and A_{12} may not be linked to each other.

[0075] In some embodiments, in Formula 1-1, a11 and a12 may be selected from 1, 2, and 3, but embodiments of the present disclosure are not limited thereto.

[0076] In some embodiments, in Formula 1-1, a13 may be 0 or 1, but embodiments of the present disclosure are not limited thereto.

[0077] In Formula 1-1, R_{11} to R_{20} may each independently be selected from hydrogen, deuterium, $-F$, $-Cl$, $-Br$, $-I$, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazino group, a hydrazono group, a substituted or unsubstituted C_1-C_{60} alkyl group, a substituted or unsubstituted C_2-C_{60} alkenyl group, a substituted or unsubstituted C_2-C_{60} alkynyl group, a substituted or unsubstituted C_1-C_{60} alkoxy group, a substituted or unsubstituted C_3-C_{10} cycloalkyl group, a substituted or unsubstituted C_1-C_{10} heterocycloalkyl group, a substituted or unsubstituted C_3-C_{10} cycloalkenyl group, a substituted or unsubstituted C_1-C_{10} heterocycloalkenyl group, a substituted or unsubstituted C_6-C_{60} aryl group, a substituted or unsubstituted C_6-C_{60} aryloxy group, a substituted or unsubstituted C_6-C_{60} arylthio group, a substituted or unsubstituted C_1-C_{60} heteroaryl group, a substituted or unsubstituted C_1-C_{60} heteroaryloxy group, a substituted or unsubstituted C_1-C_{60} heteroarylthio group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group, $-Si(Q_1)(Q_2)(Q_3)$, $-B(Q_1)(Q_2)$, $-N(Q_1)(Q_2)$, $-P(Q_1)(Q_2)$, $-C(=O)(Q_1)$, $-S(=O)(Q_1)$, $-S(=O)_2(Q_1)$, $-P(=O)(Q_1)(Q_2)$, and $-P(=S)(Q_1)(Q_2)$. In some embodiments, at least two adjacent groups selected from R_{11} to R_{20} may optionally be bound to form a substituted or unsubstituted C_5-C_{60} carbocyclic group or a substituted or unsubstituted C_1-C_{60} heterocyclic group.

[0078] With respect to R_{11} to R_{20} , Q_1 to Q_3 may each independently be selected from hydrogen, deuterium, $-F$, $-Cl$, $-Br$, $-I$, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazino group, a hydrazono group, a C_1-C_{60} alkyl group, a C_2-C_{60} alkenyl group, a C_2-C_{60} alkynyl group, a C_1-C_{60} alkoxy group, a C_3-C_{10} cycloalkyl group, a C_1-C_{10} heterocycloalkyl group, a C_3-C_{10} cycloalkenyl group, a C_1-C_{10} heterocycloalkenyl group, a C_6-C_{60} aryl group, a C_6-C_{60} aryloxy group, a C_6-C_{60} arylthio group, a C_1-C_{60} heteroaryl group, a C_1-C_{60} heteroaryloxy group, a C_1-C_{60} heteroarylthio group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, a biphenyl group, and a terphenyl group.

indenopyrrolyl group, an indolopyrrolyl group, an indenocarbazolyl group, an indolocarbazolyl group, $-\text{Si}(\text{Q}_{31})(\text{Q}_{32})(\text{Q}_{33})$, $-\text{N}(\text{Q}_{31})(\text{Q}_{32})$, $-\text{B}(\text{Q}_{31})(\text{Q}_{32})$, $-\text{C}(=\text{O})(\text{Q}_{31})$, $-\text{S}(=\text{O})(\text{Q}_{31})$, $-\text{S}(=\text{O})_2(\text{Q}_{31})$, $-\text{P}(=\text{O})(\text{Q}_{31})(\text{Q}_{32})$, and $-\text{P}(=\text{S})(\text{Q}_{31})(\text{Q}_{32})$; and
[0083] $-\text{Si}(\text{Q}_1)(\text{Q}_2)(\text{Q}_3)$, $-\text{N}(\text{Q}_1)(\text{Q}_2)$, $-\text{B}(\text{Q}_1)(\text{Q}_2)$, $-\text{C}(=\text{O})(\text{Q}_1)$, $-\text{S}(=\text{O})(\text{Q}_1)$, $-\text{S}(=\text{O})_2(\text{Q}_1)$, $-\text{P}(=\text{O})(\text{Q}_1)(\text{Q}_2)$, and $-\text{P}(=\text{S})(\text{Q}_1)(\text{Q}_2)$,


[0084] wherein Q_1 to Q_3 and Q_{31} to Q_{33} may each independently be selected from hydrogen, deuterium, $-\text{F}$, $-\text{Cl}$, $-\text{Br}$, $-\text{I}$, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazino group, a hydrazono group, a C_1 - C_{60} alkyl group, a C_2 - C_{60} alkenyl group, a C_2 - C_{60} alkynyl group, a C_1 - C_{60} alkoxy group, a C_3 - C_{10} cycloalkyl group, a C_1 - C_{10} heterocycloalkyl group, a C_3 - C_{10} cycloalkenyl group, a C_1 - C_{10} heterocycloalkenyl group, a C_6 - C_{60} aryl group, a C_1 - C_{60} heteroaryl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, a biphenyl group, and a terphenyl group, but embodiments of the present disclosure are not limited thereto.

[0085] In some embodiments, in Formula 1-1, R_{11} to R_{20} may each independently be selected from hydrogen, deuterium, $-\text{F}$, $-\text{Cl}$, $-\text{Br}$, $-\text{I}$, a cyano group, and a C_1 - C_{20} alkyl group;

[0086] a C_1 - C_{20} alkyl group substituted with at least one selected from deuterium, $-\text{F}$, $-\text{Cl}$, $-\text{Br}$, $-\text{I}$, and a cyano group;

[0087] groups represented by Formulae 5-1 to 5-138; and

[0088] $-\text{Si}(\text{Q}_1)(\text{Q}_2)(\text{Q}_3)$, $-\text{N}(\text{Q}_1)(\text{Q}_2)$, $-\text{B}(\text{Q}_1)(\text{Q}_2)$, $-\text{C}(=\text{O})(\text{Q}_1)$, $-\text{S}(=\text{O})(\text{Q}_1)$, $-\text{S}(=\text{O})_2(\text{Q}_1)$, $-\text{P}(=\text{O})(\text{Q}_1)(\text{Q}_2)$, and $-\text{P}(=\text{S})(\text{Q}_1)(\text{Q}_2)$, but embodiments of the present disclosure are not limited thereto:



5-1


5-2

5-3


5-4

5-5


-continued




5-6




5-7




5-8




5-9




5-10



5-11














5-12




5-13

-continued




-continued

5-14




5-25

5-15




5-26

5-16




5-27

5-17




5-28

5-18




5-29

5-19




5-30

5-20




5-31

5-21




5-32

5-22




5-33

5-23



5-34


5-24




5-35

5-36


-continued



5-37




5-38




5-39




5-40




5-41




5-42




5-43




5-44




5-45




5-46



5-47




5-48




5-49


-continued




5-50




5-51




5-52




5-53




5-54




5-55




5-56



5-57














5-58




5-59

-continued




-continued

5-60




5-71

5-61




5-72

5-62




5-73

5-63




5-74

5-64




5-75

5-65




5-76

5-66




5-77

5-67




5-78

5-68



5-79












5-69



5-80


5-70

-continued




-continued

5-81




5-92

5-82




5-93

5-83




5-94

5-84




5-95

5-85




5-96

5-86




5-97

5-87




5-98

5-88




5-99

5-89



5-100


5-90




5-101

5-91


-continued




5-102




5-103




5-104




5-105




5-106



5-107




5-108




5-109


-continued




5-110




5-111




5-112




5-113




5-114



5-115




5-116




5-117


-continued




5-118




5-119




5-120




5-121




5-122



5-123




5-124




5-125


-continued




5-126




5-127



5-128




5-129




5-122

5-130




5-123

5-131




5-132




5-133


-continued




5-134




5-135



5-136



5-137



5-138

[0089] In Formulae 5-1 to 5-138,

[0090] X_{51} may be selected from O, S, $N(R_{51})$, and $C(R_{51})R_{60}$,

[0091] X_{52} may be N or $C(R_{52})$, X_{53} may be N or $C(R_{53})$, X_{54} may be N or $C(R_{54})$, X_{55} may be N or $C(R_{55})$, X_{56} may be N or $C(R_{56})$, X_{57} may be N or $C(R_{57})$, X_{58} may be N or $C(R_{58})$, and X_{59} may be N or $C(R_{59})$,

[0092] R_{51} to R_{60} may each independently be selected from hydrogen, deuterium, $-F$, $-Cl$, $-Br$, $-I$, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazino group, a hydrazono group, a C_1 - C_{20} alkyl group, a C_1 - C_{20} alkoxy group, a phenyl group, a biphenyl group, a terphenyl group, a naphthyl group, a fluorenyl group, a spiro-bifluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a perylenyl group, a thiophenyl group, a furanyl group, a silolyl group, a carbazolyl group, an indolyl group, an isoindolyl group, a benzofuranyl group, a benzothiophenyl group, a benzosilolyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, a dibenzosilolyl group, $-Si(Q_{31})(Q_{32})(Q_{33})$, $-N(Q_{31})(Q_{32})$, $-B(Q_{31})(Q_{32})$, $-C(=O)(Q_{31})$, $-S(=O)(Q_{31})$, $-S(=O)_2(Q_{31})$, $-P(=O)(Q_{31})(Q_{32})$, and $-P(=S)(Q_{31})(Q_{32})$,

[0093] wherein Q_1 to Q_3 and Q_{31} to Q_{33} may each independently be selected from a C_1 - C_{60} alkyl group, a phenyl group, a biphenyl group, and a terphenyl group,

[0094] b_{51} may be selected from 1, 2, 3, 4, and 5,

[0095] b_{52} may be selected from 1, 2, 3, 4, 5, 6, and 7,

[0096] b_{53} may be selected from 1, 2, 3, 4, 5, 6, 7, 8, and 9,

[0097] b_{54} may be selected from 1, 2, 3, and 4,

[0098] b_{55} may be selected from 1, 2, and 3,

[0099] b_{56} may be selected from 1 and 2,

[0100] b_{57} may be selected from 1, 2, 3, 4, 5, and 6, and

[0101] * indicates a binding site to an adjacent atom.

[0102] In some embodiments, in Formula 1-1, R_{11} to R_{20} may each independently be selected from hydrogen, deuterium, $-F$, $-Cl$, $-Br$, $-I$, a cyano group, and a C_1 - C_{20} alkyl group;

[0103] a C_1 - C_{20} alkyl group substituted with at least one selected from deuterium, $-F$, $-Cl$, $-Br$, $-I$, and a cyano group; and

[0104] a group represented by Formula 5-1, but embodiments of the present disclosure are not limited thereto.

[0105] In some embodiments, in Formula 1-1, R_{11} and R_{12} may each independently be selected from hydrogen, deuterium, $-F$, $-Cl$, $-Br$, $-I$, a cyano group, and a C_1 - C_{20} alkyl group;

[0106] a C_1 - C_{20} alkyl group substituted with at least one selected from deuterium, $-F$, $-Cl$, $-Br$, $-I$, and a cyano group; and


[0107] a group represented by Formula 5-1, and

[0108] R_{13} to R_{16} may each be hydrogen, but embodiments of the present disclosure are not limited thereto.


[0109] In some embodiments, in Formula 1-1, R_{11} to R_{20} may each independently be selected from hydrogen, deuterium, $-F$, $-Cl$, $-Br$, $-I$, a cyano group, a methyl group, an ethyl group, an n-propyl group, an iso-propyl group, an n-butyl group, iso-butyl group, a sec-butyl group, and a tert-butyl group;

[0110] a methyl group, an ethyl group, an n-propyl group, an iso-propyl group, an n-butyl group, iso-butyl group, a sec-butyl group, and a tert-butyl group, each substituted with at least one selected from deuterium, $-F$, $-Cl$, $-Br$, $-I$, and a cyano group; and


[0111] groups represented by Formulae 6-1 to 6-257, but embodiments of the present disclosure are not limited thereto:



6-1













6-2




6-3

-continued




-continued

6-4




6-14

6-5




6-15

6-6




6-16

6-7



6-17


6-8



6-18


6-9

6-10




6-19

6-11




6-20

6-12












6-21

6-13




6-22

-continued




-continued

6-23




6-32

6-24




6-33

6-25




6-34

6-26




6-35

6-27




6-36

6-28



6-37


6-29



6-38










6-30

6-31




6-39

-continued




-continued


6-40




6-41




6-42




6-43




6-44




6-45





6-46













6-47



6-48




-continued




-continued

6-59




6-69

6-60




6-70

6-61




6-71

6-62




6-72

6-63




6-73

6-64




6-74

6-65




6-75

6-66




6-76

6-67










6-76

6-68




6-77

-continued




-continued

6-78




6-86

6-79




6-87

6-80




6-88

6-81




6-89

6-82




6-90

6-83




6-91

6-84











6-92

6-85




6-93

-continued




-continued

6-94




6-102

6-95




6-103

6-96




6-104

6-97




6-105

6-98




6-106

6-99




6-107

6-100















6-108

6-101




6-109

-continued




-continued

6-110




6-122

6-111




6-123

6-112




6-124

6-113




6-125

6-114




6-126

6-115




6-127

6-116




6-128

6-117




6-129

6-118




6-130

6-119




6-131

6-120



6-132


6-121




6-133

6-134


-continued




6-135




6-136




6-137




6-138




6-139




6-140




6-141




6-142



6-143




6-144




6-145


-continued




6-146




6-147




6-148



6-149




6-150




6-151


-continued




6-152




6-153




6-154



6-155




6-156




6-157


-continued




6-158




6-159




6-160



6-161









6-162




6-163

-continued




-continued

6-164




6-170

6-165




6-171

6-166




6-172

6-167




6-173

6-168




6-174


6-169




6-175



6-176




6-177




6-178


-continued




6-179




6-180




6-181




6-182




6-183




6-184



6-185




6-186




6-187


-continued




6-188




6-189




6-190




6-191




6-192




6-193



6-194




6-195




6-196


-continued




6-197




6-198




6-199




6-200




6-201



6-202




6-203




6-204


-continued




6-205




6-206




6-207




6-208




6-209



6-210




6-211




6-212


-continued




6-213




6-214



6-215




6-216




6-217


-continued




6-218




6-219



6-220




6-221




6-222

-continued




6-223


-continued




6-228




6-224




6-229




6-225




6-230




6-226



6-231










6-227




6-232

-continued




-continued

6-233




6-240

6-234




6-241

6-235




6-242

6-236




6-243

6-237




6-244

6-238




6-245

6-239




6-246


-continued




6-247




6-248




6-249




6-250




6-251



6-252




6-253




6-254


-continued



6-255



6-256



6-257

[0112] In Formulae 6-1 to 6-257,

[0113] “i-Pr” represents an iso-propyl group,

[0114] “t-Bu” represents a tert-butyl group,

[0115] “Ph” represents a phenyl group,

[0116] “1-Naph” represents a 1-naphthyl group,

[0117] “2-Naph” represents a 2-naphthyl group, and

[0118] * indicates a binding site to an adjacent atom.

[0119] In some embodiments, in Formula 1-1, R_{11} to R_{16} may each independently be selected from hydrogen, deuterium, —F, —Cl, —Br, —I, a cyano group, a methyl group, an ethyl group, an n-propyl group, an iso-propyl group, an n-butyl group, iso-butyl group, a sec-butyl group, and a tert-butyl group;

[0120] a methyl group, an ethyl group, an n-propyl group, an iso-propyl group, an n-butyl group, iso-butyl group, a sec-butyl group, and a tert-butyl group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, and a cyano group; and

[0121] groups represented by Formulae 6-1 to 6-110, but embodiments of the present disclosure are not limited thereto;

[0122] In some embodiments, in Formula 1-1, R_{11} and R_{12} may each independently be selected from hydrogen, deuterium, —F, —Cl, —Br, —I, a cyano group, a methyl group, an ethyl group, an n-propyl group, an iso-propyl group, an n-butyl group, iso-butyl group, a sec-butyl group, and a tert-butyl group;

[0123] a methyl group, an ethyl group, an n-propyl group, an iso-propyl group, an n-butyl group, iso-butyl group, a sec-butyl group, and a tert-butyl group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, and a cyano group; and

[0124] groups represented by Formulae 6-1 to 6-31, but embodiments of the present disclosure are not limited thereto.

[0125] In some embodiments, in Formula 1-1, R_{13} to R_{16} may each be hydrogen, but embodiments of the present disclosure are not limited thereto.


[0126] In Formula 1-1, b11 to b16 may respectively indicate the number of $R_{11}(s)$ to $R_{16}(S)$. b11 to b16 may each

independently be selected from 1, 2, 3, 4, 5, 6, 7, and 8. When any of b11 to b16 are 2 or greater, the at least two R₁₁(s) to R₁₆(s) may be identical to or different from each other.


[0127] In Formula 1-1, *1 to *4 may each independently be a binding site to M₁.

[0128] In Formula 1-1, * and *' each indicate a binding site to an adjacent atom.


[0129] In some embodiments, in Formula 1, L₁ may be a ligand represented by one selected from Formulae 1-11 and 1-12, but embodiments of the present disclosure are not limited thereto:




Formula 1-21



Formula 1-11



Formula 1-22



Formula 1-12

[0133] In Formulae 1-21 and 1-22,


[0134] *1 to *4, A₁₁, A₁₂, A₁₅, A₁₆, Y₁₁ to Y₁₄, L₁₁, L₁₂, a11, a12, R₁₁ to R₁₆, and b1 to b16 may each independently be the same defined in connection with Formula 1-1.

[0135] In some embodiments, L₁ may be a ligand represented by one selected from Formulae 1-31 and 1-32, but embodiments of the present disclosure are not limited thereto:


[0130] In Formulae 1-11 and 1-12,

[0131] *1 to *4, A₁₁ to A₁₆, Y₁₁ to Y₁₄, L₁₁, L₁₂, a11, a12, R₁₁ to R₁₆, and b11 to b16 may each independently be the same as defined in connection with Formula 1-1.

[0132] In some embodiments, in Formula 1, L₁ may be a ligand represented by one selected from Formulae 1-21 and 1-22, but embodiments of the present disclosure are not limited thereto:



Formula 1-31



Formula 1-32





[0136] In Formulae 1-31 and 1-32,

[0137] *1 to *4, A₁₁, A₁₂, Y₁₃, Y₁₄, L₁₁, L₁₂, a₁₁, a₁₂, R₁₁, R₁₂, and b₁₁ to b₁₆ may each independently be defined the same as defined in connection with Formula 1-1, and







[0138] R_{13a}, R_{13b}, R_{14a}, R_{14b}, R_{15a} to R_{15d}, and R_{16a} to R_{16d} may each independently be the same as R₁₃ in Formula 1-1.

[0139] In Formula 1, L₂ may be selected from a monodentate ligand and a bidentate ligand.

[0140] In some embodiments, in Formula 1, L₂ may be a ligand represented by one selected from Formulae 7-1 to 7-11, but embodiments of the present disclosure are not limited thereto:



-continued



[0141] In Formulae 7-1 to 7-11,

[0142] A₇₁ and A₇₂ may each independently be selected from a C₅-C₂₀ carbocyclic group and a C₁-C₂₀ heterocyclic group,

[0143] X₇₁ and X₇₂ may each independently be selected from C and N,

[0144] X₇₃ may be N or C(Q₇₃), X₇₄ may be N or C(Q₇₄), X₇₅ may be N or C(Q₇₅), X₇₆ may be N or C(Q₇₆), and X₇₇ may be N or C(Q₇₇),

[0145] X₇₈ may be O, S, or N(Q₇₈), and X₇₉ may be O, S, or N(Q₇₉),

[0146] Y₇₁ and Y₇₂ may each independently be selected from a single bond, a double bond, a substituted or unsubstituted C₁-C₅ alkylene group, a substituted or unsubstituted C₂-C₅ alkenylene group, and a substituted or unsubstituted C₆-C₁₀ arylene group,

[0147] Z₇₁ and Z₇₂ may each independently be selected from N, O, N(R₇₅), P(R₇₅)(R₇₆), and As(R₇₅)(R₇₆),

[0148] Z₇₃ may be selected from P and As,

[0149] Z₇₄ may be selected from CO (e.g., a carbonyl moiety, C(=O)) and C(R₇₅)(R₇₆),

[0150] R₇₁ to R₈₀ and Q₇₃ to Q₇₉ may each independently be selected from hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino

group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a substituted or unsubstituted C₁-C₆₀ alkyl group, a substituted or unsubstituted C₂-C₆₀ alkenyl group, a substituted or unsubstituted C₂-C₆₀ alkynyl group, a substituted or unsubstituted C₁-C₆₀ alkoxy group, a substituted or unsubstituted C₃-C₁₀ cycloalkyl group, a substituted or unsubstituted C₁-C₁₀ heterocycloalkyl group, a substituted or unsubstituted C₃-C₁₀ cycloalkenyl group, a substituted or unsubstituted C₁-C₁₀ heterocycloalkenyl group, a substituted or unsubstituted C₆-C₆₀ aryl group, a substituted or unsubstituted C₆-C₆₀ aryloxy group, a substituted or unsubstituted C₆-C₆₀ arylthio group, a substituted or unsubstituted C₁-C₆₀ heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, and a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group, wherein R₇₁ and R₇₂ may optionally be bound to form a ring, R₇₇ and R₇₈ may optionally be bound to form a ring, R₇₈ and R₇₉ may optionally be bound to form a ring, and R₇₉ and R₈₀ may optionally be bound to form a ring,

[0151] b71 and b72 may each independently be selected from 1, 2, and 3, and

[0152] * and *[†] each indicate a binding site to an adjacent atom.

[0153] In some embodiments, in Formula 7-1, A₇₁ and A₇₂ may each independently be selected from a benzene group, a naphthalene group, an imidazole group, a benzimidazole group, a pyridine group, a pyrimidine group, a triazine group, a quinoline group, and an isoquinoline group, but embodiments of the present disclosure are not limited thereto.

[0154] In some embodiments, in Formula 7-1, X₇₂ and X₇₉ may each be N, but embodiments of the present disclosure are not limited thereto.

[0155] In some embodiments, in Formula 7-7, X₇₃ may be C(Q₇₃), X₇₄ may be C(Q₇₄), X₇₅ may be C(Q₇₅), X₇₆ may be C(Q₇₆), and X₇₇ may be C(Q₇₇), but embodiments of the present disclosure are not limited thereto.

[0156] In some embodiments, in Formula 7-8, X₇₈ may be N(Q₇₈), and X₇₉ may be N(Q₇₉), but embodiments of the present disclosure are not limited thereto.

[0157] In some embodiments, in Formulae 7-2, 7-3, and 7-8, Y₇₁ and Y₇₂ may each independently be selected from a substituted or unsubstituted methylene group and a substituted or unsubstituted phenylene group, but embodiments of the present disclosure are not limited thereto.

[0158] In some embodiments, in Formulae 7-1 and 7-2, Z₇₁ and Z₇₂ may each be O, but embodiments of the present disclosure are not limited thereto.

[0159] In some embodiments, in Formula 7-4, Z₇₃ may be P, but embodiments of the present disclosure are not limited thereto.

[0160] In some embodiments, in Formulae 7-1 to 7-8, R₇₁ to R₈₀ and Q₇₃ to Q₇₉ may each independently be selected from hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₂₀ alkyl group, and a C₁-C₂₀ alkoxy group;

[0161] a C₁-C₂₀ alkyl group and a C₁-C₂₀ alkoxy group, each substituted with at least one selected from deuterium,











—F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a phenyl group, a naphthyl group, a pyridinyl group, and a pyrimidinyl group;

[0162] a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, and an imidazopyridinyl group; and

[0163] a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, and an imidazopyridinyl group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a C₁-C₂₀ alkyl group, a C₁-C₂₀ alkoxy group, a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl


group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, and an imidazopyridinyl group, but embodiments of the present disclosure are not limited thereto.

[0164] In some embodiments, in Formula 1, L_2 may be a ligand represented by one selected from Formulae 8-1 to 8-11, but embodiments of the present disclosure are not limited thereto:



-continued

8-11



[0165] In Formulae 8-1 to 8-11, * indicates a binding site to an adjacent atom.

[0166] In Formula 1, n_1 indicates the number of L_1 (s), and n_1 may be 1.

[0167] In Formula 1, n_2 indicates the number of L_2 (s), and n_2 may be selected from 0, 1, and 2.

[0168] In some embodiments, in Formula 1, n_1 may be 1, and n_2 may be 0, but embodiments of the present disclosure are not limited thereto.

[0169] In some embodiments, in Formula 1, n_1 may be 1, and n_2 may be 1 or 2, but embodiments of the present disclosure are not limited thereto.

[0170] In some embodiments, in Formula 1, M_1 may be selected from Pt and Pd, n_1 may be 1, and n_2 may be 0, but embodiments of the present disclosure are not limited thereto.

[0171] In some embodiments, the organometallic compound represented by Formula 1 may be selected from Compounds 1 to 240, but embodiments of the present disclosure are not limited thereto:

8-1

8-2

8-3

8-4

8-5

8-6

8-7



8-8

8-9


8-10

1

2




-continued




3


-continued




7




4




8




5



9




6




10


-continued




11



12




13




14


-continued




15



16







17




18

-continued




-continued

19




23

20




24

21




25

22




26

-continued




27


-continued




31




28




32




29



33







30







34

-continued



-continued



35

39

36

40


37

41

38


42

-continued




43


-continued




47




44




48




45



49







46




50

-continued




-continued

51




55

52




56

53




57

54




58

-continued




59


-continued




63




60




64




61



65







62




66

-continued




-continued

67




71

68




72

69







73

70



74


-continued



-continued


75

79




76

80




77

81




78


82




-continued




83



84




85




86


-continued




87



88







89




90

-continued




-continued

91




95

92




96

93




97

94




98

-continued




99


-continued




103




100




104




101



105




102




106

-continued




107


-continued




111




108




112




109



113







110



114


-continued



-continued


115

119




116

120




117

121




118

122




-continued




123


-continued




127




124




128




125



129




126




130


-continued




131



132




133




134


-continued




135



136







137




138

-continued




-continued

139




143

140




144

141







145

142




146

-continued




-continued

147




151

148




152

149







153

150




154

-continued




-continued

155




159

156




160

157




161

158




162

-continued




163

-continued




167

164





168





169

165







170

166




-continued



-continued


171

175




172

176




173

177




174

178




-continued




179


-continued




183




180




184




181



185




182




186

-continued




187

-continued




191

188




192




193



189




194



190




-continued




195

-continued




199


196




200




197




201




198




202




-continued




203



204




205




206


-continued




207



208




209




210

-continued




211

-continued




215

212





216





213

217




218

214




-continued




219

-continued




223

220





224





221

225




222

226




-continued




227


-continued




231




228




232




229



233




230




234


-continued




235



236




237




238

-continued



239



240

[0172] The organometallic compound represented by Formula 1 may emit blue light having a maximum emission wavelength of about 450 nm or greater and less than 490 nm.

[0173] The organometallic compound represented by Formula 1 includes an azaborine moiety. When the organometallic compound represented by Formula 1 is included in an emission layer of an organic light-emitting device, formation of an excimer and an exciplex with a host may be suppressed. Accordingly, the colorimetric purity and lifespan of an organic light-emitting device including the organometallic compound may be improved.

[0174] In the organometallic compound represented by Formula 1, a metal atom may bind to an α -position of a boron (B) or nitrogen (N) atom. As such, metal-ligand charge transfer in the complex may be improved. Accordingly, the luminescent efficiency and lifespan of an organic light-emitting device including the organometallic compound may be improved.

[0175] In the organometallic compound represented by Formula 1, B and N may be directly linked to each other via a single bond, and the organometallic compound may have a multi-ring structure in which the B and N atoms are surrounded by rings. Accordingly, the organometallic compound may have improved structural durability. Accordingly, an organic light-emitting device including the organometallic compound may have improved luminescent efficiency.

[0176] The organometallic compound represented by Formula 1 may be synthesized using any suitable organic synthetic method. Methods of synthesizing the organometallic compound may be understood by those having ordinary skill in the art by referring to Examples described herein.

[0177] At least one organometallic compound represented by Formula 1 may be included between a pair of electrodes in an organic light-emitting device. In some embodiments, the organometallic compound may be included in at least one selected from a hole transport region, an electron transport region, and an emission layer.

[0178] In some embodiments, the organometallic compound represented by Formula 1 may be used as a material for forming a capping layer positioned on one or both outer side of the pair of electrodes in an organic light-emitting device.

[0179] In some embodiments, the emission layer may include the organometallic compound, but embodiments of the present disclosure are not limited thereto.

[0180] In some embodiments, the emission layer may include a host and the organometallic compound, and an amount of the host in the emission layer may be greater than an amount of the organometallic compound in the emission layer, but embodiments of the present disclosure are not limited thereto.

[0181] As used herein, expressions such as “at least one organometallic compound represented by Formula 1” and “(layer) may include at least one organometallic compound” indicate that “(the organic layer) may include one organometallic compound of Formula 1, or may include two or more different organometallic compounds of Formula 1”.

[0182] For example, a single organometallic compound, referred to as Compound 1, may be included in the organic layer. In this embodiment, Compound 1 may be included in the emission layer of the organic light-emitting device. In some embodiments, two organometallic compounds, referred to as Compounds 1 and 2, may both be included in the organic layer. In this embodiment, Compounds 1 and 2 may be present in the same layer (for example, Compounds 1 and 2 may both be (e.g., simultaneously) present in the emission layer), or may be present in different layers (for example, Compound 1 may be present in the emission layer, and Compound 2 may be present in an electron transport layer).

[0183] The organic layer may include: i) a hole transport region between the first electrode (anode) and the emission layer, which may include at least one selected from a hole injection layer, a hole transport layer, a buffer layer, and an electron blocking layer, and ii) an electron transport region between the emission layer and the second electrode (cathode), which may include at least one selected from a hole blocking layer, an electron transport layer, and an electron injection layer. The emission layer may include the at least one organometallic compound represented by Formula 1.

[0184] The term “organic layer” as used herein may refer to a single layer and/or a plurality of layers between the first electrode and the second electrode in an organic light-emitting device. Materials included in the “organic layer” are not limited to being an organic material.

Description of FIG. 1

[0185] FIG. 1 is a schematic view of an organic light-emitting device 10 according to an example embodiment of

the present disclosure. The organic light-emitting device 10 may include a first electrode 110, an organic layer 150, and a second electrode 190.

[0186] Hereinafter, the structure of the organic light-emitting device 10 according to an embodiment of the present disclosure and a method of manufacturing an organic light-emitting device according to an embodiment of the present disclosure will be described in connection with FIG. 1.

First Electrode 110

[0187] In FIG. 1, a substrate may be positioned under the first electrode 110 or above the second electrode 190. The substrate may be a glass substrate and/or a plastic substrate having excellent mechanical strength, thermal stability, transparency, surface smoothness, ease of handling, and/or water resistance.

[0188] The first electrode 110 may be formed by depositing and/or sputtering, onto the substrate, a material for forming the first electrode 110. When the first electrode 110 is an anode, the material for forming the first electrode 110 may be selected from materials with a high work function to facilitate hole injection.

[0189] The first electrode 110 may be a reflective electrode, a semi-transmissive electrode, or a transmissive electrode. When the first electrode 110 is a transmissive electrode, the material for forming the first electrode 110 may be selected from indium tin oxide (ITO), indium zinc oxide (IZO), tin oxide (SnO₂), zinc oxide (ZnO), and combinations thereof, but embodiments of the present disclosure are not limited thereto. In some embodiments, when the first electrode 110 is a semi-transmissive electrode or a reflective electrode, at least one selected from magnesium (Mg), silver (Ag), aluminum (Al), aluminum-lithium (Al—Li), calcium (Ca), magnesium-indium (Mg—In), magnesium-silver (Mg—Ag), and combinations thereof may be used as a material for forming the first electrode 110, but embodiments of the present disclosure are not limited thereto.

[0190] The first electrode 110 may have a single-layered structure, or a multi-layered structure including two or more layers. In some embodiments, the first electrode 110 may have a triple-layered structure of ITO/Ag/ITO, but embodiments of the present disclosure are not limited thereto.

Organic Layer 150

[0191] The organic layer 150 may be on the first electrode 110. The organic layer 150 may include an emission layer.

[0192] In some embodiments, the organic layer 150 may further include a hole transport region between the first electrode 110 and the emission layer, and/or an electron transport region between the emission layer and the second electrode 190.

Hole Transport Region in Organic Layer 150


[0193] The hole transport region may have: i) a single-layered structure including a single layer including a single material, ii) a single-layered structure including a single layer including a plurality of different materials, or iii) a multi-layered structure having a plurality of layers including a plurality of different materials.

[0194] The hole transport region may include at least one selected from a hole injection layer, a hole transport layer, an emission auxiliary layer, and/or an electron blocking layer.


[0195] For example, the hole transport region may have a single-layered structure including a single layer including a plurality of different materials, or a multi-layered structure, e.g., a hole injection layer/hole transport layer structure, a hole injection layer/hole transport layer/emission auxiliary layer structure, a hole injection layer/emission auxiliary layer structure, a hole transport layer/emission auxiliary layer structure, or a hole injection layer/hole transport layer/electron blocking layer structure, wherein layers of each structure are sequentially stacked on the first electrode **110** in each stated order, but embodiments of the present disclosure are not limited thereto.

[0196] The hole transport region may include at least one selected from m-MTDATA, TDATA, 2-TNATA, NPB (NPD), p-NPB, TPD, a spiro-TPD, a spiro-NPB, methylated-NPB, TAPC, HMTPD, 4,4',4''-tris(N-carbazolyl)triphenylamine (TCTA), polyaniline/dodecylbenzenesulfonic acid (PANI/DBSA), poly(3,4-ethylenedioxythiophene)/poly(4-styrenesulfonate) (PEDOT/PSS), polyaniline/camphor sulfonic acid (PANI/CSA), (polyaniline)/poly(4-styrenesulfonate) (PANI/PSS), a compound represented by Formula 201, and a compound represented by Formula 202:


-continued




2-TNATA





m-MTDATA



NPB



TDATA

 β -NPB

TPD

group, a naphthacenylenylene group, a picenylene group, a perylenylene group, a pentaphenylenylene group, a hexacenylenylene group, a pentacenylenylene group, a rubicenylenylene group, a coronenylenylene group, an ovalenylenylene group, a thiophenylenylene group, a furanylenylene group, a carbazolylenylene group, an indolylenylene group, an isoindolylenylene group, a benzofuranylenylene group, a benzothiophenylenylene group, a dibenzofuranylenylene group, a dibenzothiophenylenylene group, a benzocarbazolylenylene group, a dibenzocarbazolylenylene group, a dibenzosilolylenylene group, and a pyridinylenylene group; and

[0206] a phenylene group, a pentalenylenylene group, an indenylene group, a naphthylene group, an azulenylenylene group, a heptalenylenylene group, an indacenylenylene group, an acenaphthylene group, a fluorenylenylene group, a spiro-bifluorenylenylene group, a benzofluorenylenylene group, a dibenzofluorenylenylene group, a phenalenylenylene group, a phenanthrenylene group, an anthracenylenylene group, a fluoranthenylenylene group, a triphenylenylene group, a pyrenylene group, a chrysenylene group, a naphthacenylenylene group, a picenylene group, a perylenylene group, a pentaphenylenylene group, a hexacenylenylene group, a pentacenylenylene group, a rubicenylenylene group, a coronenylenylene group, an ovalenylenylene group, a thiophenylenylene group, a furanylenylene group, a carbazolylenylene group, an indolylenylene group, an isoindolylenylene group, a benzofuranylenylene group, a benzothiophenylenylene group, a dibenzofuranylenylene group, a dibenzothiophenylenylene group, a benzocarbazolylenylene group, a dibenzocarbazolylenylene group, a dibenzosilolylenylene group, and a pyridinylenylene group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazino group, a hydrazono group, a C₁-C₂₀ alkyl group, a C₁-C₂₀ alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclopentenyl group, a cyclohexenyl group, a phenyl group, a biphenyl group, a terphenyl group, a phenyl group substituted with a C₁-C₁₀ alkyl group, a phenyl group substituted with —F, a pentalenyl group, an indenyl group, a naphthyl group, an azulenyl group, a heptalenyl group, an indacenyl group, an acenaphthyl group, a fluorenyl group, a spiro-bifluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenalenylyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a naphthacenylyl group, a picenyl group, a perylenyl group, a pentaphenyl group, a hexacenylyl group, a pentacenylyl group, a rubicenylyl group, a coronenyl group, an ovalenyl group, a thiophenyl group, a furanyl group, a carbazolyl group, an indolyl group, an isoindolyl group, a benzofuranyl group, a benzothiophenyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, a dibenzosilolyl group, a pyridinyl group, —Si(Q₃₁)(Q₃₂)(Q₃₃), and —N(Q₃₁)(Q₃₂),

[0207] wherein Q₃₁ to Q₃₃ may each independently be selected from a C₁-C₁₀ alkyl group, a C₁-C₁₀ alkoxy group, a phenyl group, a biphenyl group, a terphenyl group, and a naphthyl group.

[0208] In some embodiments, xa1 to xa4 may each independently be 0, 1, or 2.

[0209] In some embodiments, xa5 may be 1, 2, 3, or 4.

[0210] In some embodiments, R₂₀₁ to R₂₀₄ and Q₂₀₁ may each independently be selected from a phenyl group, a biphenyl group, a terphenyl group, a pentalenyl group, an indenyl group, a naphthyl group, an azulenyl group, a heptalenyl group, an indacenyl group, an acenaphthyl group,

a fluorenyl group, a spiro-bifluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenalenylyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a naphthacenylyl group, a picenyl group, a perylenyl group, a pentaphenyl group, a hexacenylyl group, a pentacenylyl group, a rubicenylyl group, a coronenyl group, an ovalenyl group, a thiophenyl group, a furanyl group, a carbazolyl group, an indolyl group, an isoindolyl group, a benzofuranyl group, a benzothiophenyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, a dibenzosilolyl group, and a pyridinyl group; and

[0211] a phenyl group, a biphenyl group, a terphenyl group, a pentalenyl group, an indenyl group, a naphthyl group, an azulenyl group, a heptalenyl group, an indacenyl group, an acenaphthyl group, a fluorenyl group, a spiro-bifluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenalenylyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a naphthacenylyl group, a picenyl group, a perylenyl group, a pentaphenyl group, a hexacenylyl group, a pentacenylyl group, a rubicenylyl group, a coronenyl group, an ovalenyl group, a thiophenyl group, a furanyl group, a carbazolyl group, an indolyl group, an isoindolyl group, a benzofuranyl group, a benzothiophenyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, a dibenzosilolyl group, and a pyridinyl group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazino group, a hydrazono group, a C₁-C₂₀ alkyl group, a C₁-C₂₀ alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclopentenyl group, a cyclohexenyl group, a phenyl group, a biphenyl group, a terphenyl group, a phenyl group substituted with a C₁-C₁₀ alkyl group, a phenyl group substituted with —F, a pentalenyl group, an indenyl group, a naphthyl group, an azulenyl group, a heptalenyl group, an indacenyl group, an acenaphthyl group, a fluorenyl group, a spiro-bifluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenalenylyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a naphthacenylyl group, a picenyl group, a perylenyl group, a pentaphenyl group, a hexacenylyl group, a pentacenylyl group, a rubicenylyl group, a coronenyl group, an ovalenyl group, a thiophenyl group, a furanyl group, a carbazolyl group, an indolyl group, an isoindolyl group, a benzofuranyl group, a benzothiophenyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, a dibenzosilolyl group, a pyridinyl group, —Si(Q₃₁)(Q₃₂)(Q₃₃), and —N(Q₃₁)(Q₃₂),

[0212] wherein Q₃₁ to Q₃₃ may each be the same as described herein.

[0213] In some embodiments, in Formula 201, at least one selected from R₂₀₁ to R₂₀₃ may each independently be selected from:

[0214] a fluorenyl group, a spiro-bifluorenyl group, a carbazolyl group, a dibenzofuranyl group, and a dibenzothiophenyl group; and

[0215] a fluorenyl group, a spiro-bifluorenyl group, a carbazolyl group, a dibenzofuranyl group, and a dibenzothiophenyl group, each substituted with at least one selected

from deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazino group, a hydrazono group, a C_1 - C_{20} alkyl group, a C_1 - C_{20} alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclopentenyl group, a cyclohexenyl group, a phenyl group, a biphenyl group, a terphenyl group, a phenyl group substituted with a C_1 - C_{10} alkyl group, a phenyl group substituted with —F, a naphthyl group, a fluorenyl group, a spiro-bifluorenyl group, a carbazoyl group, a dibenzofuranyl group, and a dibenzothiophenyl group, but embodiments of the present disclosure are not limited thereto.


[0216] In some embodiments, in Formula 202, i) R_{201} and R_{202} may be bound via a single bond, and/or ii) R_{203} and R_{204} may be bound via a single bond.

[0217] In some embodiments, in Formula 202, at least one selected from R_{201} to R_{204} may be selected from:


[0218] a carbazolyl group; and

[0219] a carbazolyl group substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazino group, a hydrazono group, a C_1 - C_{20} alkyl group, a C_1 - C_{20} alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclopentenyl group, a cyclohexenyl group, a phenyl group, a biphenyl group, a terphenyl group, a phenyl group substituted with a C_1 - C_{10} alkyl group, a phenyl group substituted with —F, a naphthyl group, a fluorenyl group, a spiro-bifluorenyl group, a carbazoyl group, a dibenzofuranyl group, and a dibenzothiophenyl group, but embodiments of the present disclosure are not limited thereto.


[0220] In some embodiments, the compound represented by Formula 201 may be further represented by Formula 201A:




[0221] In some embodiments, the compound represented by Formula 201 may be further represented by Formula 201A(1), but embodiments of the present disclosure are not limited thereto:




[0222] In some embodiments, the compound represented by Formula 201 may be further represented by Formula 201A-1, but embodiments of the present disclosure are not limited thereto:



[0223] In some embodiments, the compound represented by Formula 202 may be further represented by Formula 202A:



[0224] In some embodiments, the compound represented by Formula 202 may be further represented by Formula 202A-1:



[0225] In Formulae 201A, 201A(1), 201A-1, 202A, and 202A-1, L_{201} to L_{203} , $xa1$ to $xa3$, $xa5$, and R_{202} to R_{204} may be the same as described herein.


[0226] R_{211} and R_{212} may each be the same as R_{203} , and

[0227] R_{213} to R_{217} may each independently be selected from hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazino group, a hydrazono group, a C_1 - C_{20} alkyl group, a C_1 - C_{20} alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclopentenyl group, a cyclohexenyl group, a phenyl group, a biphenyl group, a terphe-


nyl group, a phenyl group substituted with a C₁-C₁₀ alkyl group, a phenyl group substituted with —F, a pentalenyl group, an indenyl group, a naphthyl group, an azulenyl group, a heptalenyl group, an indacenyl group, an acenaphthyl group, a fluorenyl group, a spiro-bifluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenalenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a naphthacenyl group, a picenyl group, a perylenyl group, a pentaphenyl group, a hexacenyl group, a pentacenyl group, a rubicenyl group, a coronenyl group, an ovalenyl group, a thiophenyl group, a furanyl group, a carbazolyl group, an indolyl group, an isoindolyl group, a benzofuranyl group, a benzothiophenyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, a dibenzosilolyl group, and a pyridinyl group.

[0228] The hole transport region may include at least one compound selected from Compounds HT1 to HT39, but embodiments of the present disclosure are not limited thereto:

HT1




HT2




-continued

HT3




HT4




-continued

HT5




-continued


HT7



HT6




HT8




-continued

HT9




-continued


HT11




HT12



HT10




HT13




-continued

HT14




-continued


HT17




HT15




HT18



HT16




HT19




-continued


HT20



HT21




HT22




-continued


HT23



HT24




HT25




-continued

HT26




-continued

HT29





HT30


HT27




HT31



HT28




HT32




-continued

HT33




-continued


HT36




HT34




HT37



HT35




HT38



-continued

HT39



[0229] The thickness of the hole transport region may be about 100 Angstroms (Å) to about 10,000 Å, for example, about 100 Å to about 1,000 Å. When the hole transport region includes at least one selected from a hole injection layer and a hole transport layer, the thickness of the hole injection layer may be about 100 Å to about 9,000 Å, for example, about 100 Å to about 1,000 Å, while the thickness of the hole transport layer may be about 50 Å to about 2,000 Å, for example, about 100 Å to about 1,500 Å. When the thicknesses of the hole transport region, the hole injection layer, and/or the hole transport layer are within any of these ranges, excellent hole transport characteristics may be obtained without a substantial increase in driving voltage.

[0230] The emission auxiliary layer may increase light emission efficiency by compensating for an optical resonance distance according to the wavelength of light emitted by an emission layer (e.g., adjusting the optical resonance distance within the device to match the wavelength of light emitted from the emission layer). The electron blocking layer may reduce or eliminate the flow of electrons from an electron transport region. The emission auxiliary layer and the electron blocking layer may each include the aforementioned materials.

p-Dopant

[0231] The hole transport region may include a charge generating material in addition to the aforementioned materials in order to improve conductive properties of the hole transport region. The charge generating material may be substantially homogeneously or non-homogeneously dispersed in the hole transport region.

[0232] The charge-generating material may be, for example, a p-dopant.

[0233] In some embodiments, a lowest unoccupied molecular orbital (LUMO) energy level of the p-dopant may be -3.5 eV or less.



[0234] The p-dopant may include at least one selected from a quinone derivative, a metal oxide, and a cyano group-containing compound, but embodiments of the present disclosure are not limited thereto.

[0235] In some embodiments, the p-dopant may be selected from a quinone derivative (such as tetracyanoquinodimethane (TCNQ) and/or 2,3,5,6-tetrafluoro-7,7,8,8-tetracyanoquinodimethane (F4-TCNQ));


[0236] a metal oxide (such as tungsten oxide and/or molybdenum oxide);

[0237] 1,4,5,8,9,11-hexaazatriphenylene-hexacarbonitrile (HAT-CN); and

[0238] a compound represented by Formula 221, but embodiments of the present disclosure are not limited thereto:



Formula 221



[0239] In Formula 221,

[0240] R_{221} to R_{223} may each independently be selected from a substituted or unsubstituted C_3 - C_{10} cycloalkyl group, a substituted or unsubstituted C_1 - C_{10} heterocycloalkyl group, a substituted or unsubstituted C_3 - C_{10} cycloalkenyl group, a substituted or unsubstituted C_1 - C_{10} heterocycloalkenyl group, a substituted or unsubstituted C_6 - C_{60} aryl group, a substituted or unsubstituted C_1 - C_{60} heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, and a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group, wherein at least one selected from R_{221} to R_{223} may include at least one substituent selected from a cyano group, $-F$, $-Cl$, $-Br$, $-I$, a C_1 - C_{20} alkyl group substituted with $-F$, a C_1 - C_{20} alkyl group substituted with $-Cl$, a C_1 - C_{20} alkyl group substituted with $-Br$, and a C_1 - C_{20} alkyl group substituted with $-I$.

Emission Layer in Organic Layer 150

[0241] When the organic light-emitting device 10 is a full color organic light-emitting device, the emission layer may be patterned into a red emission layer, a green emission layer, and/or a blue emission layer, according to a sub-pixel. In one or more embodiments, the emission layer may have a stacked structure. The stacked structure may include two or more layers selected from a red emission layer, a green emission layer, and a blue emission layer. In some embodi-

ments, the two or more layers may be in direct contact with each other. In some embodiments, the two or more layers may be separated from each other. In one or more embodiments, the emission layer may include two or more materials. The two or more materials may include a red light-emitting material, a green light-emitting material, and/or a blue light-emitting material. In some embodiments, the two or more materials may be mixed with each other in a single layer. The two or more materials mixed with each other in the single layer may emit white light.


[0242] The emission layer may include a host and a dopant. The dopant may include the organometallic compound represented by Formula 1. In some embodiments, the dopant may include at least one of a phosphorescent dopant and a fluorescent dopant, in addition to the organometallic compound represented by Formula 1.

[0243] The amount of the dopant in the emission layer may be about 0.01 parts to about 15 parts by weight based on 100 parts by weight of the host, but embodiments of the present disclosure are not limited thereto.

[0244] The thickness of the emission layer may be about 100 Å to about 1,000 Å, and in some embodiments, about 200 Å to about 600 Å. When the thickness of the emission layer is within these ranges, improved luminescence characteristics may be obtained without a substantial increase in driving voltage.

Host in Emission Layer

[0245] The host may include a compound represented by Formula 301:



[0246] In Formula 301,

[0247] Ar_{301} may be selected from a substituted or unsubstituted $\text{C}_5\text{-C}_{60}$ carbocyclic group and a substituted or unsubstituted $\text{C}_1\text{-C}_{60}$ heterocyclic group,

[0248] $\text{xb}11$ may be 1, 2, or 3,

[0249] L_{301} may be selected from a substituted or unsubstituted $\text{C}_3\text{-C}_{10}$ cycloalkylene group, a substituted or unsubstituted $\text{C}_1\text{-C}_{10}$ heterocycloalkylene group, a substituted or unsubstituted $\text{C}_3\text{-C}_{10}$ cycloalkenylene group, a substituted or unsubstituted $\text{C}_1\text{-C}_{10}$ heterocycloalkenylene group, a substituted or unsubstituted $\text{C}_6\text{-C}_{60}$ arylene group, a substituted or unsubstituted $\text{C}_1\text{-C}_{60}$ heteroarylene group, a substituted or unsubstituted divalent non-aromatic condensed polycyclic group, and a substituted or unsubstituted divalent non-aromatic condensed heteropolycyclic group,

[0250] $\text{xb}1$ may be an integer from 0 to 5,

[0251] R_{301} may be selected from deuterium, $-\text{F}$, $-\text{Cl}$, $-\text{Br}$, $-\text{I}$, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazino group, a hydrazono group, a substituted or unsubstituted $\text{C}_1\text{-C}_{60}$ alkyl group, a substituted or unsubstituted $\text{C}_2\text{-C}_{60}$ alkenyl group, a substituted or unsubstituted $\text{C}_2\text{-C}_{60}$ alkynyl group, a substituted or unsub-

stituted $\text{C}_1\text{-C}_{60}$ alkoxy group, a substituted or unsubstituted $\text{C}_3\text{-C}_{10}$ cycloalkyl group, a substituted or unsubstituted $\text{C}_1\text{-C}_{10}$ heterocycloalkyl group, a substituted or unsubstituted $\text{C}_3\text{-C}_{10}$ cycloalkenyl group, a substituted or unsubstituted $\text{C}_1\text{-C}_{10}$ heterocycloalkenyl group, a substituted or unsubstituted $\text{C}_6\text{-C}_{60}$ aryl group, a substituted or unsubstituted $\text{C}_6\text{-C}_{60}$ aryloxy group, a substituted or unsubstituted $\text{C}_6\text{-C}_{60}$ arylthio group, a substituted or unsubstituted $\text{C}_1\text{-C}_{60}$ heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group, $-\text{Si}(\text{Q}_{301})(\text{Q}_{302})(\text{Q}_{303})$, $-\text{N}(\text{Q}_{301})(\text{Q}_{302})$, $-\text{B}(\text{Q}_{301})(\text{Q}_{302})$, $-\text{C}(=\text{O})(\text{Q}_{301})$, $-\text{S}(=\text{O})_2(\text{Q}_{301})$, and $-\text{P}(=\text{O})(\text{Q}_{301})(\text{Q}_{302})$, and

[0252] $\text{xb}21$ may be an integer from 1 to 5,

[0253] wherein Q_{301} to Q_{303} may each independently be selected from a $\text{C}_1\text{-C}_{10}$ alkyl group, a $\text{C}_1\text{-C}_{10}$ alkoxy group, a phenyl group, a biphenyl group, a terphenyl group, and a naphthyl group, but embodiments of the present disclosure are not limited thereto.

[0254] In some embodiments, in Formula 301, Ar_{301} may be selected from:

[0255] a naphthalene group, a fluorene group, a spiro-bifluorene group, a benzofluorene group, a dibenzofluorene group, a phenalene group, a phenanthrene group, an anthracene group, a fluoranthene group, a triphenylene group, a pyrene group, a chrysene group, a naphthacene group, a picene group, a perylene group, a pentaphene group, an indenoanthracene group, a dibenzofuran group, and a dibenzothiophene group; and


[0256] a naphthalene group, a fluorene group, a spiro-bifluorene group, a benzofluorene group, a dibenzofluorene group, a phenalene group, a phenanthrene group, an anthracene group, a fluoranthene group, a triphenylene group, a pyrene group, a chrysene group, a naphthacene group, a picene group, a perylene group, a pentaphene group, an indenoanthracene group, a dibenzofuran group, and a dibenzothiophene group, each substituted with at least one selected from deuterium, $-\text{F}$, $-\text{Cl}$, $-\text{Br}$, $-\text{I}$, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazino group, a hydrazono group, a $\text{C}_1\text{-C}_{20}$ alkyl group, a $\text{C}_1\text{-C}_{20}$ alkoxy group, a phenyl group, a biphenyl group, a terphenyl group, a naphthyl group, $-\text{Si}(\text{Q}_{31})(\text{Q}_{32})(\text{Q}_{33})$, $-\text{N}(\text{Q}_{31})(\text{Q}_{32})$, $-\text{B}(\text{Q}_{31})(\text{Q}_{32})$, $-\text{C}(=\text{O})(\text{Q}_{31})$, $-\text{S}(=\text{O})_2(\text{Q}_{31})$, and $-\text{P}(=\text{O})(\text{Q}_{31})(\text{Q}_{32})$,

[0257] wherein Q_{31} to Q_{33} may each independently be selected from a $\text{C}_1\text{-C}_{10}$ alkyl group, a $\text{C}_1\text{-C}_{10}$ alkoxy group, a phenyl group, a biphenyl group, a terphenyl group, and a naphthyl group, but embodiments of the present disclosure are not limited thereto.

[0258] When $\text{xb}11$ in Formula 301 is 2 or greater, the at least two $\text{Ar}_{301}(\text{S})$ may be bound (linked) via a single bond.


[0259] In one or more embodiments, the compound represented by Formula 301 may be further represented by Formula 301-1 or Formula 301-2:

Formula 301-1



-continued

Formula 301-2



[0260] In Formulae 301-1 and 301-2,

[0261] A_{301} to A_{304} may each independently be selected from a benzene group, a naphthalene group, a phenanthrene group, a fluoranthene group, a triphenylene group, a pyrene group, a chrysene group, a pyridine group, a pyrimidine group, an indene group, a fluorene group, a spiro-bifluorene group, a benzofluorene group, a dibenzofluorene group, an indole group, a carbazole group, a benzocarbazole group, a dibenzocarbazole group, a furan group, a benzofuran group, a dibenzofuran group, a naphthofuran group, a benzonaphthofuran group, a dinaphthofuran group, a thiophene group, a benzothiophene group, a dibenzothiophene group, a naphthothiophene group, a benzonaphthothiophene group, and a dinaphthothiophene group,

[0262] X_{301} may be O, S, or N- $[(L_{304})_{xb4}-R_{304}]$,

[0263] R_{311} to R_{314} may each independently be selected from hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazino group, a hydrazono group, a C_1 - C_{20} alkyl group, a C_1 - C_{20} alkoxy group, a phenyl group, a biphenyl group, a terphenyl group, a naphthyl group —Si(Q_{31})(Q_{32})(Q_{33}), —N(Q_{31})(Q_{32}), —B(Q_{31})(Q_{32}), —C(=O)(Q_{31}), —S(=O)₂(Q_{31}), and —P(=O)(Q_{31})(Q_{32}),

[0264] $xb22$ and $xb23$ may each independently be 0, 1, or 2,

[0265] L_{301} , $xb1$, R_{301} , and Q_{31} to Q_{33} may each be the same as described herein,

[0266] L_{302} to L_{304} may each independently be the same as L_{301} ,

[0267] $xb2$ to $xb4$ may each independently be the same as $xb1$, and

[0268] R_{302} to R_{304} may each independently be the same as R_{301} .

[0269] In some embodiments, in Formulae 301, 301-1, and 301-2, L_{301} to L_{304} may each independently be selected from:

[0270] a phenylene group, a naphthylene group, a fluorenylene group, a spiro-bifluorenylene group, a benzofluorenylene group, a dibenzofluorenylene group, a phenanthrenylene group, an anthracenylylene group, a fluoranthenylylene group, a triphenylenylene group, a pyrenylene group, a chrysenylene group, a perylenylene group, a pentaphenylylene group, a hexacenylylene group, a pentacenylylene group, a thiophenylylene group, a furanylylene group, a carbazolylylene group, an indolylylene group, an isoindolylylene group, a benzofuranylylene group, a benzothiophenylylene group, a dibenzofuranylylene group, a dibenzothiophenylylene group, a benzocarbazolylylene group, a dibenzocarbazolylylene group, a dibenzosilolylylene group, a pyridinylylene group, an imidazolylylene group, a pyrazolylylene group, a thiazolylylene group,

an isothiazolylylene group, an oxazolylylene group, an isoxazolylylene group, a thiadiazolylylene group, an oxadiazolylylene group, a pyrazinylylene group, a pyrimidinylylene group, a pyridazinylylene group, a triazinylylene group, a quinolinylene group, an isoquinolinylene group, a benzoquinolinylene group, a phthalazinylylene group, a naphthyridinylylene group, a quinoxalinylylene group, a quinazolinylene group, a cinnolinylene group, a phenanthridinylylene group, an acridinylylene group, a phenanthrolinylylene group, a phenazinylylene group, a benzimidazolylylene group, an isobenzothiazolylylene group, a benzoxazolylylene group, an isobenzoxazolylylene group, a triazolylylene group, a tetrazolylylene group, an imidazopyridinylylene group, an imidazopyrimidinylylene group, and an azacarbazolylylene group; and

[0271] a phenylene group, a naphthylene group, a fluorenylylene group, a spiro-bifluorenylylene group, a benzofluorenylylene group, a dibenzofluorenylylene group, a phenanthrenylene group, an anthracenylylene group, a fluoranthenylylene group, a triphenylenylene group, a pyrenylene group, a chrysenylene group, a perylenylene group, a pentaphenylylene group, a hexacenylylene group, a pentacenylylene group, a thiophenylylene group, a furanylylene group, a carbazolylylene group, an indolylylene group, an isoindolylylene group, a benzofuranylylene group, a benzothiophenylylene group, a dibenzofuranylylene group, a dibenzothiophenylylene group, a benzocarbazolylylene group, a dibenzocarbazolylylene group, a dibenzosilolylylene group, a pyridinylylene group, an imidazolylylene group, a pyrazolylylene group, a thiazolylylene group, an isothiazolylylene group, an oxazolylylene group, an isoxazolylylene group, a thiadiazolylylene group, an oxadiazolylylene group, a pyrazinylylene group, a pyrimidinylylene group, a pyridazinylylene group, a triazinylylene group, a quinolinylene group, an isoquinolinylene group, a benzoquinolinylene group, a phthalazinylylene group, a naphthyridinylylene group, a quinoxalinylylene group, a quinazolinylene group, a cinnolinylene group, a phenanthridinylylene group, an acridinylylene group, a phenanthrolinylylene group, a phenazinylylene group, a benzimidazolylylene group, an isobenzothiazolylylene group, a benzoxazolylylene group, an isobenzoxazolylylene group, a triazolylylene group, a tetrazolylylene group, an imidazopyridinylylene group, an imidazopyrimidinylylene group, and an azacarbazolylylene group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazino group, a hydrazono group, a C_1 - C_{20} alkyl group, a C_1 - C_{20} alkoxy group, a phenyl group, a biphenyl group, a terphenyl group, a naphthyl group, a fluorenyl group, a spiro-bifluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenylylene group, a fluoranthenylylene group, a triphenylenylene group, a pyre-

nyl group, a chrysenyl group, a perylenyl group, a pentaphenyl group, a hexacenylyl group, a pentacenylyl group, a thiophenyl group, a furanyl group, a carbazolyl group, an indolyl group, an isoindolyl group, a benzofuranyl group, a benzothiophenyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, a dibenzosilolyl group, a pyridinyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a thiadiazolyl group, an oxadiazolyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a triazinyl group, a quinolyl group, an isoquinolyl group, a benzoquinolyl group, a phthalazinyl group, a naphthyridinyl group, a quinoxalyl group, a quinazolyl group, a cinnolyl group, a phenanthridinyl group, an acridinyl group, a phenanthrolinyl group, a phenazinyl group, a benzimidazolyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, an azacarbazolyl group, $-\text{Si}(\text{Q}_{31})(\text{Q}_{32})(\text{Q}_{33})$, $-\text{N}(\text{Q}_{31})(\text{Q}_{32})$, $-\text{B}(\text{Q}_{31})(\text{Q}_{32})$, $-\text{C}(=\text{O})(\text{Q}_{31})$, $-\text{S}(=\text{O})_2(\text{Q}_{31})$, and $-\text{P}(=\text{O})(\text{Q}_{31})(\text{Q}_{32})$,

[0272] wherein Q_{31} to Q_{33} may each be the same as described herein.

[0273] In some embodiments, in Formulae 301, 301-1, and 301-2, R_{301} to R_{304} may each independently be selected from:

[0274] a phenyl group, a biphenyl group, a terphenyl group, a naphthyl group, a fluorenyl group, a spiro-bifluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthrenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a perylenyl group, a pentaphenyl group, a hexacenylyl group, a pentacenylyl group, a thiophenyl group, a furanyl group, a carbazolyl group, an indolyl group, an isoindolyl group, a benzofuranyl group, a benzothiophenyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, a dibenzosilolyl group, a pyridinyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a thiadiazolyl group, an oxadiazolyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a triazinyl group, a quinolyl group, an isoquinolyl group, a benzoquinolyl group, a phthalazinyl group, a naphthyridinyl group, a quinoxalyl group, a quinazolyl group, a cinnolyl group, a phenanthridinyl group, an acridinyl group, a phenanthrolinyl group, a phenazinyl group, a benzimidazolyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, and an azacarbazolyl group; and

[0275] a phenyl group, a biphenyl group, a terphenyl group, a naphthyl group, a fluorenyl group, a spiro-bifluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthrenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a perylenyl group, a pentaphenyl group, a hexacenylyl group, a pentacenylyl group, a thiophenyl group, a furanyl group, a carbazolyl group, an indolyl group, an isoindolyl group, a benzofuranyl group, a benzothiophenyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, a dibenzosilolyl group, a pyridinyl group, an imidazolyl


group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a thiadiazolyl group, an oxadiazolyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a triazinyl group, a quinolyl group, an isoquinolyl group, a benzoquinolyl group, a phthalazinyl group, a naphthyridinyl group, a quinoxalyl group, a quinazolyl group, a cinnolyl group, a phenanthridinyl group, an acridinyl group, a phenanthrolinyl group, a phenazinyl group, a benzimidazolyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, and an azacarbazolyl group, each substituted with at least one selected from deuterium, $-\text{F}$, $-\text{Cl}$, $-\text{Br}$, $-\text{I}$, a hydroxyl group, a cyano group, a nitro group, an amino group, a hydrazino group, a hydrazono group, a C_1 - C_{20} alkyl group, a C_1 - C_{20} alkoxy group, a phenyl group, a biphenyl group, a terphenyl group, a naphthyl group, a fluorenyl group, a spiro-bifluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthrenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a perylenyl group, a pentaphenyl group, a hexacenylyl group, a pentacenylyl group, a thiophenyl group, a furanyl group, a carbazolyl group, an indolyl group, an isoindolyl group, a benzofuranyl group, a benzothiophenyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, a dibenzosilolyl group, a pyridinyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a thiadiazolyl group, an oxadiazolyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a triazinyl group, a quinolyl group, an isoquinolyl group, a benzoquinolyl group, a phthalazinyl group, a naphthyridinyl group, a quinoxalyl group, a quinazolyl group, a cinnolyl group, a phenanthridinyl group, an acridinyl group, a phenanthrolinyl group, a phenazinyl group, a benzimidazolyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, an azacarbazolyl group, $-\text{Si}(\text{Q}_{31})(\text{Q}_{32})(\text{Q}_{33})$, $-\text{N}(\text{Q}_{31})(\text{Q}_{32})$, $-\text{B}(\text{Q}_{31})(\text{Q}_{32})$, $-\text{C}(=\text{O})(\text{Q}_{31})$, $-\text{S}(=\text{O})_2(\text{Q}_{31})$, and $-\text{P}(=\text{O})(\text{Q}_{31})(\text{Q}_{32})$,

[0276] wherein Q_{31} to Q_{33} may each be the same as described herein.


[0277] In some embodiments, the host may include an alkaline earth metal complex. For example, the host may include a beryllium (Be) complex, e.g., Compound H55 or a magnesium (Mg) complex. In some embodiments, the host may include a zinc (Zn) complex.

[0278] The host may include at least one selected from 9,10-di-(2-naphthyl)anthracene (ADN), 2-methyl-9,10-bis(naphthalen-2-yl)anthracene (MADN), 9,10-di-(2-naphthyl)-2-t-butyl-anthracene (TBADN), 4,4'-bis(N-carbazolyl)-1,1'-biphenyl (CBP), 1,3-di-9-carbazolylbenzene (mCP), 1,3,5-tri(carbazol-9-yl)benzene (TCP), bis(4-(9H-carbazol-9-yl)phenyl)diphenylsilane, POPCPA(4-(1-(4-(diphenylamino)phenyl)cyclohexyl)phenyl)diphenyl-phosphine oxide (BCPDS), and Compounds H1 to H55, but embodiments of the present disclosure are not limited thereto:

BCPDS




POPCPA




-continued


H5




H6




H7




H8




H9




H10




H1




H2








H3








H4



-continued




-continued




-continued


H21




H22



H23




H24




-continued


H25



H26




-continued




H27

-continued




H30




H31

H28





H32




H33

H29




H34




-continued


H35




H36



H37




H38




-continued


H39




H40



H41



-continued




H42

H43

H44

H45

-continued



H46

H47

H48


H49

H50


H51

-continued


H52




H53



H54



H55



[0279] In some embodiments, the host may include at least one selected from a silicon-containing compound (e.g., BCPDS and/or the like, as used in the Examples) and a phosphine oxide-containing compound (e.g., POPCPA and/or the like, as used in the Examples).

[0280] The host may include one type or class of compounds, or in some embodiments, may include two or more different types or classes of compounds (for example, the


Examples include BCPDS and POPCPA as hosts). As such, embodiments of the present disclosure may be modified in various ways.

Phosphorescent Dopant Included in Emission Layer of Organic Layer 150


[0281] The phosphorescent dopant may include the organometallic compound represented by Formula 1.

[0282] In some embodiments, the phosphorescent dopant may further include, in addition to the organometallic compound represented by Formula 1, an organometallic complex represented by Formula 401:

Formula 401



Formula 402



[0283] In Formulae 401 and 402,

[0284] M may be selected from iridium (Ir), platinum (Pt), palladium (Pd), osmium (Os), titanium (Ti), zirconium (Zr), hafnium (Hf), europium (Eu), terbium (Tb), rhodium (Rh), and thulium (Tm),

[0285] L_{401} may be selected from ligands represented by Formula 402, and xc1 may be 1, 2, or 3; where when xc1 is 2 or greater, at least two $L_{401}(s)$ may be identical to or different from each other,

[0286] L_{402} may be an organic ligand, and xc2 may be an integer selected from 0 to 4; where when xc2 is 2 or greater, at least two $L_{402}(S)$ may be identical to or different from each other,

[0287] X_{401} to X_{404} may each independently be a nitrogen atom (N) or a carbon atom (C),

[0288] X_{401} and X_{403} may be bound to each other via a single bond or a double bond, and X_{402} and X_{404} may be bound to each other via a single bond or a double bond,

[0289] A_{401} and A_{402} may each independently be a C_5 - C_{60} carbocyclic group or a C_1 - C_{60} heterocyclic group,

[0290] X_{405} may be selected from a single bond, $*-O-*$, $*-S-*$, $*-C(=O)-*$, $*-N(Q_{411})-*$, $*-C(Q_{411})(Q_{412})-*$, $*-C(Q_{411})=C(Q_{412})-*$, $*-O(Q_{411})-*$, and $*=C(Q_{411})-*$, wherein Q_{411} and Q_{412} may be selected from hydrogen, deuterium, a C_1 - C_{20} alkyl group, a C_1 - C_{20} alkoxy group, a phenyl group, a biphenyl group, a terphenyl group, and a naphthyl group,

[0291] X_{406} may be a single bond, O, or S,

[0292] R_{401} and R_{402} may each independently be selected from hydrogen, deuterium, $-F$, $-Cl$, $-Br$, $-I$, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazino group, a hydrazono group, a substituted or unsubstituted C_1 - C_{20} alkyl group, a substituted or unsubstituted

C_1 - C_{20} alkoxy group, a substituted or unsubstituted C_3 - C_{10} cycloalkyl group, a substituted or unsubstituted C_1 - C_{10} heterocycloalkyl group, a substituted or unsubstituted C_3 - C_{10} cycloalkenyl group, a substituted or unsubstituted C_1 - C_{10} heterocycloalkenyl group, a substituted or unsubstituted C_6 - C_{60} aryl group, a substituted or unsubstituted C_6 - C_{60} aryloxy group, a substituted or unsubstituted C_1 - C_{60} arylthio group, a substituted or unsubstituted C_1 - C_{60} heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group, $-\text{Si}(\text{Q}_{401})(\text{Q}_{402})(\text{Q}_{403})$, $-\text{N}(\text{Q}_{401})(\text{Q}_{402})$, $-\text{B}(\text{Q}_{401})(\text{Q}_{402})$, $-\text{C}(=\text{O})(\text{Q}_{401})$, $-\text{S}(=\text{O})_2(\text{Q}_{401})$, and $-\text{P}(=\text{O})(\text{Q}_{401})(\text{Q}_{402})$, wherein Q_{401} to Q_{403} may each independently be selected from a C_1 - C_{10} alkyl group, a C_1 - C_{10} alkoxy group, a C_6 - C_{20} aryl group, and a C_1 - C_{20} heteroaryl group,

[0293] xc11 and xc12 may each independently be an integer from 0 to 10, and

[0294] * and *' in Formula 402 each indicate a binding site to M in Formula 401.

[0295] In some embodiments, in Formula 402, A_{401} and A_{402} may each independently be selected from a benzene group, a naphthalene group, a fluorene group, a spirobifluorene group, an indene group, a pyrrole group, a thiophene group, a furan group, an imidazole group, a pyrazole group, a thiazole group, an isothiazole group, an oxazole group, an isoxazole group, a pyridine group, a pyrazine group, a pyrimidine group, a pyridazine group, a quinoline group, an isoquinoline group, a benzoquinoline group, a quinoxaline group, a quinazoline group, a carbazole group, a benzimidazole group, a benzofuran group, a benzothiophene group, an isobenzothiophene group, a benzoxazole group, an isobenzoxazole group, a triazole group, a tetrazole group, an oxadiazole group, a triazine group, a dibenzofuran group, and a dibenzothiophene group.

[0296] In one or more embodiments, in Formula 402, i) X_{401} may be nitrogen, and X_{402} may be carbon, or ii) X_{401} and X_{402} may both (e.g., simultaneously) be nitrogen.

[0297] In some embodiments, in Formula 402, R_{401} and R_{402} may each independently be selected from:

[0298] hydrogen, deuterium, $-\text{F}$, $-\text{Cl}$, $-\text{Br}$, $-\text{I}$, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazino group, a hydrazono group, a C_1 - C_{20} alkyl group, and a C_1 - C_{20} alkoxy group;

[0299] a C_1 - C_{20} alkyl group and a C_1 - C_{20} alkoxy group, each substituted with at least one selected from deuterium, $-\text{F}$, $-\text{Cl}$, $-\text{Br}$, $-\text{I}$, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazino group, a hydrazono group, a phenyl group, a naphthyl group, a cyclopentyl group, a cyclohexyl group, an adamantyl group, a norbornanyl group, and a norbornenyl group;

[0300] a cyclopentyl group, a cyclohexyl group, an adamantyl group, a norbornanyl group, a norbornenyl group, a phenyl group, a biphenyl group, a terphenyl group, a naphthyl group, a fluorenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a triazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazolyl group, a dibenzofuranyl group, and a dibenzothiophenyl group;

[0301] a cyclopentyl group, a cyclohexyl group, an adamantyl group, a norbornanyl group, a norbornenyl group, a phenyl group, a biphenyl group, a terphenyl group, a naphthyl group, a fluorenyl group, a pyridinyl group, a pyrazinyl

group, a pyrimidinyl group, a pyridazinyl group, a triazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazolyl group, a dibenzofuranyl group, and a dibenzothiophenyl group, each substituted with at least one selected from deuterium, $-\text{F}$, $-\text{Cl}$, $-\text{Br}$, $-\text{I}$, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazino group, a hydrazono group, a C_1 - C_{20} alkyl group, a C_1 - C_{20} alkoxy group, a cyclopentyl group, a cyclohexyl group, an adamantyl group, a norbornanyl group, a norbornenyl group, a phenyl group, a biphenyl group, a terphenyl group, a naphthyl group, a fluorenyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a triazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a carbazolyl group, a dibenzofuranyl group, and a dibenzothiophenyl group; and

[0302] $-\text{Si}(\text{Q}_{401})(\text{Q}_{402})(\text{Q}_{403})$, $-\text{N}(\text{Q}_{401})(\text{Q}_{402})$, $-\text{B}(\text{Q}_{401})(\text{Q}_{402})$, $-\text{C}(=\text{O})(\text{Q}_{401})$, $-\text{S}(=\text{O})_2(\text{Q}_{401})$, and $-\text{P}(=\text{O})(\text{Q}_{401})(\text{Q}_{402})$,


[0303] wherein Q_{401} to Q_{403} may each independently be selected from a C_1 - C_{10} alkyl group, a C_1 - C_{10} alkoxy group, a phenyl group, a biphenyl group, and a naphthyl group, but embodiments of the present disclosure are not limited thereto.

[0304] In one or more embodiments, when xc1 in Formula 401 is 2 or greater, two $A_{401}(\text{S})$ of the at least two $L_{401}(\text{s})$ may optionally be bound via X_{407} as a linking group, or two $A_{402}(\text{S})$ may optionally be bound via X_{408} as a linking group (see, e.g., Compounds PD1 to PD4 and PD7). X_{407} and X_{408} may each independently be selected from a single bond, $^*-\text{O}-^*$, $^*-\text{S}-^*$, $^*-\text{C}(=\text{O})-^*$, $^*-\text{N}(\text{Q}_{413})-^*$, $^*-\text{C}(\text{Q}_{413})(\text{Q}_{414})-^*$, and $^*-\text{C}(\text{Q}_{413})=\text{C}(\text{Q}_{414})-^*$, wherein Q_{413} and Q_{414} may each independently be hydrogen, deuterium, a C_1 - C_{20} alkyl group, a C_1 - C_{20} alkoxy group, a phenyl group, a biphenyl group, a terphenyl group, or a naphthyl group, but embodiments of the present disclosure are not limited thereto.






[0305] L_{402} in Formula 401 may be any suitable monovalent, divalent, or trivalent organic ligand. For example, L_{402} may be selected from a halogen, a diketone (e.g., acetylacetonate), a carboxylic acid (e.g., picolinate), $-\text{C}(=\text{O})$, an isonitrile group, $-\text{CN}$, and a phosphorus-containing group (e.g., phosphine or phosphite), but embodiments of the present disclosure are not limited thereto.

[0306] In some embodiments, the phosphorescent dopant may include, for example, at least one selected from Compounds PD1 to PD25, but embodiments of the present disclosure are not limited thereto:

PD1




-continued




-continued

PD2




PD7

PD3



PD8


PD4



PD9


PD10

PD5








PD11

PD6




PD12

-continued




-continued

PD13




PD18

PD14



PD19


PD15



PD20





PD16

PD17



PD21

-continued




Fluorescent Dopant in Emission Layer

[0307] The fluorescent dopant may include an arylamine compound or a styrylamine compound.

PD22

[0308] In some embodiments, the fluorescent dopant may include a compound represented by Formula 501:



Formula 501

PD23

[0309] In Formula 501,

[0310] Ar_{501} may be selected from a substituted or unsubstituted C_5 - C_{60} carbocyclic group and a substituted or unsubstituted C_1 - C_{60} heterocyclic group,

[0311] L_{501} to L_{503} may each independently be selected from a substituted or unsubstituted C_3 - C_{10} cycloalkylene group, a substituted or unsubstituted C_1 - C_{10} heterocycloalkylene group, a substituted or unsubstituted C_3 - C_{10} cycloalkenylene group, a substituted or unsubstituted C_1 - C_{10} heterocycloalkenylene group, a substituted or unsubstituted C_6 - C_{60} arylene group, a substituted or unsubstituted C_1 - C_{60} heteroarylene group, a substituted or unsubstituted divalent non-aromatic condensed polycyclic group, and a substituted or unsubstituted divalent non-aromatic condensed heteropolycyclic group,

[0312] x_{d1} to x_{d3} may each independently be an integer from 0 to 3,

[0313] R_{501} and R_{502} may each independently be selected from a substituted or unsubstituted C_3 - C_{10} cycloalkyl group, a substituted or unsubstituted C_1 - C_{10} heterocycloalkyl group, a substituted or unsubstituted C_3 - C_{10} cycloalkenyl group, a substituted or unsubstituted C_1 - C_{10} heterocycloalkenyl group, a substituted or unsubstituted C_6 - C_{60} aryl group, a substituted or unsubstituted C_6 - C_{60} aryloxy group, a substituted or unsubstituted C_6 - C_{60} arylthio group, a substituted or unsubstituted C_1 - C_{60} heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, and a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group, and

[0314] x_{d4} may be an integer from 1 to 6.

PD24

[0315] In some embodiments, in Formula 501, Ar_{501} may be selected from:

PD25

[0316] a naphthalene group, a heptalene group, a fluorene group, a spiro-bifluorene group, a benzofluorene group, a dibenzofluorene group, a phenalene group, a phenanthrene group, an anthracene group, a fluoranthene group, a triphenylene group, a pyrene group, a chrysene group, a naphthacene group, a picene group, a perylene group, a pentaphene group, an indenoanthracene group, and an indenophenanthrene group; and

[0317] a naphthalene group, a heptalene group, a fluorene group, a spiro-bifluorene group, a benzofluorene group, a dibenzofluorene group, a phenalene group, a phenanthrene group, an anthracene group, a fluoranthene group, a triphenylene group, a pyrene group, a chrysene group, a naphthacene group, a picene group, a perylene group, a pentaphene group, an indenoanthracene group, and an indenophenanthrene group, each substituted with at least one selected from deuterium, $-\text{F}$, $-\text{Cl}$, $-\text{Br}$, $-\text{I}$, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazino group, a hydrazono group, a C_1 - C_{20} alkyl group, a C_1 - C_{20} alkoxy group, a phenyl group, a biphenyl group, a terphenyl group, and a naphthyl group.

[0318] In one or more embodiments, in Formula 501, L_{501} to L_{503} may each independently be selected from:

[0319] a phenylene group, a naphthylene group, a fluorenylene group, a spiro-bifluorenylene group, a benzofluorenylene group, a dibenzofluorenylene group, a phenanthrenylene group, an anthracenylenylene group, a fluoranthenylenylene group, a triphenylenylene group, a pyrenylene group, a chrysenylene group, a perylenylene group, a pentaphenylenylene group, a hexacenylenylene group, a pentacenylenylene group, a thiophenylenylene group, a furanylenylene group, a carbazolylenylene group, an indolylenylene group, an isoindolylenylene group, a benzofuranylenylene group, a benzothiophenylenylene group, a dibenzofuranylenylene group, a dibenzothiophenylenylene group, a benzocarbazolylenylene group, a dibenzocarbazolylenylene group, a dibenzosilolylenylene group, and a pyridinylenylene group; and

[0320] a phenylene group, a naphthylene group, a fluorenylene group, a spiro-bifluorenylene group, a benzofluorenylene group, a dibenzofluorenylene group, a phenanthrenylene group, an anthracenylenylene group, a fluoranthenylenylene group, a triphenylenylene group, a pyrenylene group, a chrysenylene group, a perylenylene group, a pentaphenylenylene group, a hexacenylenylene group, a pentacenylenylene group, a thiophenylenylene group, a furanylenylene group, a carbazolylenylene group, an indolylenylene group, an isoindolylenylene group, a benzofuranylenylene group, a benzothiophenylenylene group, a dibenzofuranylenylene group, a dibenzothiophenylenylene group, a benzocarbazolylenylene group, a dibenzocarbazolylenylene group, a dibenzosilolylenylene group, and a pyridinylenylene group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazino group, a hydrazono group, a C_1 - C_{20} alkyl group, a C_1 - C_{20} alkoxy group, a phenyl group, a biphenyl group, a terphenyl group, a naphthyl group, a fluorenyl group, a spiro-bifluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenylyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a perylenyl group, a pentaphenyl group, a pentacenyl group, a thiophenyl group, a furanyl group, a carbazolyl group, an indolyl group, an isoindolyl group, a benzofuranyl group, a benzothiophenyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, a dibenzosilolyl group, and a pyridinyl group.

[0321] In some embodiments, in Formula 501, R_{501} and R_{502} may each independently be selected from:

[0322] a phenyl group, a biphenyl group, a terphenyl group, a naphthyl group, a fluorenyl group, a spiro-bifluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenylyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a perylenyl group, a pentaphenyl group, a hexacenyl group, a pentacenyl group, a thiophenyl group, a furanyl group, a carbazolyl group, an indolyl group, an isoindolyl group, a benzofuranyl group, a benzothiophenyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, a dibenzosilolyl group, and a pyridinyl group; and

[0323] a phenyl group, a biphenyl group, a terphenyl group, a naphthyl group, a fluorenyl group, a spiro-bifluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenylyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a perylenyl group, a pentaphenyl group, a hexacenyl group, a pentacenyl group, a thiophenyl group, a furanyl group, a carbazolyl group, an indolyl group, an isoindolyl group, a benzofuranyl group, a benzothiophenyl group, a dibenzofuranyl group, a dibenzothiophenyl group,


a benzocarbazolyl group, a dibenzocarbazolyl group, a dibenzosilolyl group, and a pyridinyl group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazino group, a hydrazono group, a C_1 - C_{20} alkyl group, a C_1 - C_{20} alkoxy group, a phenyl group, a biphenyl group, a terphenyl group, a naphthyl group, a fluorenyl group, a spiro-bifluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenylyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a perylenyl group, a pentaphenyl group, a hexacenyl group, a pentacenyl group, a thiophenyl group, a furanyl group, a carbazolyl group, an indolyl group, an isoindolyl group, a benzofuranyl group, a benzothiophenyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, a dibenzosilolyl group, a pyridinyl group, and —Si(Q_{31})(Q_{32})(Q_{33}),

[0324] wherein Q_{31} to Q_{33} may be selected from a C_1 - C_{10} alkyl group, a C_1 - C_{10} alkoxy group, a phenyl group, a biphenyl group, a terphenyl group, and a naphthyl group.


[0325] In one or more embodiments, $xd4$ in Formula 501 may be 2, but embodiments of the present disclosure are not limited thereto.

[0326] In some embodiments, the fluorescent dopant may be selected from Compounds FD1 to FD22:


FD1



FD2




-continued




FD3

-continued





FD5

FD6




FD4

FD7




-continued

FD8




-continued


FD12




FD13




FD14




FD15




FD16




FD9






FD10



FD11




-continued




FD17


-continued



FD18



FD19




FD20

FD21


FD22

[0327] In some embodiments, the fluorescent dopant may be selected from the following compounds, but embodiments of the present disclosure are not limited thereto:



DPVBi

-continued



Electron Transport Region in Organic Layer 150

[0328] The electron transport region may have: i) a single-layered structure including a single layer including a single material, ii) a single-layered structure including a single layer including a plurality of different materials, or iii) a multi-layered structure each having a plurality of layers, each having a plurality of different materials.

[0329] The electron transport region may include at least one selected from a buffer layer, a hole blocking layer, an electron control layer, an electron transport layer, and an electron injection layer, but embodiments of the present disclosure are not limited thereto.

[0330] In some embodiments, the electron transport region may have an electron transport layer/electron injection layer structure, a hole blocking layer/electron transport layer/electron injection layer structure, an electron control layer/electron transport layer/electron injection layer structure, or a buffer layer/electron transport layer/electron injection layer structure, wherein layers of each structure are sequentially stacked on the emission layer in each stated order, but embodiments of the present disclosure are not limited thereto.

[0331] The electron transport region (for example, the buffer layer, the hole blocking layer, the electron control

layer, and/or the electron transport layer in the electron transport region) may include a metal-free compound including at least one π electron-depleted nitrogen-containing ring.

[0332] The term “ π electron-depleted nitrogen-containing ring” as used herein refers to a C_1 - C_{60} heterocyclic group having at least one $*-N=*$ moiety as a ring-forming moiety.

[0333] For example, the “ π electron-depleted nitrogen-containing ring” may be: i) a 5-membered to 7-membered heteromonocyclic group having at least one $*-N=*$ moiety, ii) a heteropolycyclic group in which at least two 5-membered to 7-membered heteromonocyclic groups, each having at least one $*-N=*$ moiety, are condensed, or iii) a heteropolycyclic group in which at least one of a 5-membered to 7-membered heteromonocyclic group, each having at least one $*-N=*$ moiety, is condensed with at least one C_5 - C_{60} carbocyclic group.

[0334] Non-limiting examples of the π electron-depleted nitrogen-containing ring include an imidazole, a pyrazole, a thiazole, an isothiazole, an oxazole, an isoxazole, a pyridine, a pyrazine, a pyrimidine, a pyridazine, an indazole, a purine, a quinoline, an isoquinoline, a benzoquinoline, a phthalazine, a naphthyridine, a quinoxaline, a quinazoline, a cin-

noline, a phenanthridine, an acridine, a phenanthroline, a phenazine, a benzimidazole, an iso-benzothiazole, a benzoxazole, an isobenzoxazole, a triazole, a tetrazole, an oxadiazole, a triazine, a thiadiazole, an imidazopyridine, an imidazopyrimidine, and an azacarbazole, but embodiments of the present disclosure are not limited thereto.

[0335] In some embodiments, the electron transport region may include a compound represented by Formula 601:



[0336] In Formula 601,

[0337] Ar_{601} may be selected from a substituted or unsubstituted C_3 - C_{60} carbocyclic group and a substituted or unsubstituted C_1 - C_{60} heterocyclic group,

[0338] $\text{xe}11$ may be 1, 2, or 3,

[0339] L_{601} may be selected from a substituted or unsubstituted C_3 - C_{10} cycloalkylene group, a substituted or unsubstituted C_1 - C_{10} heterocycloalkylene group, a substituted or unsubstituted C_3 - C_{10} cycloalkenylene group, a substituted or unsubstituted C_1 - C_{10} heterocycloalkenylene group, a substituted or unsubstituted C_6 - C_{60} arylene group, a substituted or unsubstituted C_1 - C_{60} heteroarylene group, a substituted or unsubstituted divalent non-aromatic condensed polycyclic group, and a substituted or unsubstituted divalent non-aromatic condensed heteropolycyclic group,

[0340] $\text{xe}1$ may be an integer from 0 to 5,

[0341] R_{601} may be selected from a substituted or unsubstituted C_3 - C_{10} cycloalkyl group, a substituted or unsubstituted C_1 - C_{10} heterocycloalkyl group, a substituted or unsubstituted C_3 - C_{10} cycloalkenyl group, a substituted or unsubstituted C_1 - C_{10} heterocycloalkenyl group, a substituted or unsubstituted C_6 - C_{60} aryl group, a substituted or unsubstituted C_6 - C_{60} aryloxy group, a substituted or unsubstituted C_6 - C_{60} arylthio group, a substituted or unsubstituted C_1 - C_{60} heteroaryl group, a substituted or unsubstituted mono-valent non-aromatic condensed polycyclic group, a substituted or unsubstituted mono-valent non-aromatic condensed heteropolycyclic group, $-\text{Si}(\text{Q}_{601})(\text{Q}_{602})(\text{Q}_{603})$, $-\text{C}(=\text{O})(\text{Q}_{601})$, $-\text{S}(=\text{O})_2(\text{Q}_{601})$, and $-\text{P}(=\text{O})(\text{Q}_{601})(\text{Q}_{602})$,

[0342] wherein Q_{601} to Q_{603} may each independently be a C_1 - C_{10} alkyl group, a C_1 - C_{10} alkoxy group, a phenyl group, a biphenyl group, a terphenyl group, or a naphthyl group, and

[0343] $\text{xe}21$ may be an integer from 1 to 5.

[0344] In some embodiments, at least one of the $\text{xe}11$ $\text{Ar}_{601}(\text{s})$ and the $\text{xe}21$ $\text{R}_{601}(\text{s})$ in Formula 601 may include the π electron-depleted nitrogen-containing ring.

[0345] In some embodiments, in Formula 601, Ar_{601} may be selected from:

[0346] a benzene group, a naphthalene group, a fluorene group, a spiro-bifluorene group, a benzofluorene group, a dibenzofluorene group, a phenalene group, a phenanthrene group, an anthracene group, a fluoranthene group, a triphenylene group, a pyrene group, a chrysene group, a naphthacene group, a picene group, a perylene group, a pentaphene group, an indenoanthracene group, a dibenzofuran group, a dibenzothiophene group, a carbazole group, an imidazole group, a pyrazole group, a thiazole group, an isothiazole group, an oxazole group, an isoxazole group, a pyridine group, a pyrazine group, a pyrimidine group, a pyridazine group, an indazole group, a purine group, a quinoline group, an isoquinoline group, a benzoquinoline group, a phthalazine group, a naphthyridine group, a quinoxaline group, a quinazoline group, a cinnoline group, a

phenanthridine group, an acridine group, a phenanthroline group, a phenazine group, a benzimidazole group, an iso-benzothiazole group, a benzoxazole group, an isobenzoxazole group, a triazole group, a tetrazole group, an oxadiazole group, a triazine group, a thiadiazole group, an imidazopyridine group, an imidazopyrimidine group, and an azacarbazole group; and

[0347] a benzene group, a naphthalene group, a fluorene group, a spiro-bifluorene group, a benzofluorene group, a dibenzofluorene group, a phenalene group, a phenanthrene group, an anthracene group, a fluoranthene group, a triphenylene group, a pyrene group, a chrysene group, a naphthacene group, a picene group, a perylene group, a pentaphene group, an indenoanthracene group, a dibenzofuran group, a dibenzothiophene group, a carbazole group, an imidazole group, a pyrazole group, a thiazole group, an isothiazole group, an oxazole group, an isoxazole group, a pyridine group, a pyrazine group, a pyrimidine group, a pyridazine group, an indazole group, a purine group, a quinoline group, an isoquinoline group, a benzoquinoline group, a phthalazine group, a naphthyridine group, a quinoxaline group, a quinazoline group, a cinnoline group, a phenanthridine group, an acridine group, a phenanthroline group, a phenazine group, a benzimidazole group, an iso-benzothiazole group, a benzoxazole group, an isobenzoxazole group, a triazole group, a tetrazole group, an oxadiazole group, a triazine group, a thiadiazole group, an imidazopyridine group, an imidazopyrimidine group, and an azacarbazole group, each substituted with at least one selected from deuterium, $-\text{F}$, $-\text{Cl}$, $-\text{Br}$, $-\text{I}$, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazino group, a hydrazono group, a C_1 - C_{20} alkyl group, a C_1 - C_{20} alkoxy group, a phenyl group, a biphenyl group, a terphenyl group, a naphthyl group, $-\text{Si}(\text{Q}_{31})(\text{Q}_{32})(\text{Q}_{33})$, $-\text{S}(=\text{O})_2(\text{Q}_{31})$, and $-\text{P}(=\text{O})(\text{Q}_{31})(\text{Q}_{32})$,


[0348] wherein Q_{31} to Q_{33} may each independently be selected from a C_1 - C_{10} alkyl group, a C_1 - C_{10} alkoxy group, a phenyl group, a biphenyl group, a terphenyl group, and a naphthyl group.

[0349] When $\text{xe}11$ in Formula 601 is 2 or greater, the at least two $\text{Ar}_{601}(\text{s})$ may be bound via a single bond.

[0350] In one or more embodiments, Ar_{601} in Formula 601 may be an anthracene group.

[0351] In one or more embodiments, the compound represented by Formula 601 may be further represented by Formula 601-1:

Formula 601-1



[0352] In Formula 601-1,

[0353] X_{614} may be N or C(R_{614}), X_{615} may be N or C(R_{615}), X_{616} may be N or C(R_{616}), and at least one selected from X_{614} to X_{616} may be N,

[0354] L_{611} to L_{613} may each independently be the same as L_{601} ,

[0355] xe611 to xe613 may each independently be the same as xe1,

[0356] R₆₁₁ to R₆₁₃ may each independently be the same as R₆₀₁, and

[0357] R₆₁₄ to R₆₁₆ may each independently be selected from hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazino group, a hydrazono group, a C₁-C₂₀ alkyl group, a C₁-C₂₀ alkoxy group, a phenyl group, a biphenyl group, a terphenyl group, and a naphthyl group.

[0358] In some embodiments, in Formulae 601 and 601-1, L₆₀₁ and L₆₁₁ to L₆₁₃ may each independently be selected from:

[0359] a phenylene group, a naphthylene group, a fluorenylene group, a spiro-bifluorenylene group, a benzofluorenylene group, a dibenzofluorenylene group, a phenanthrenylene group, an anthracenylenylene group, a fluoranthenylenylene group, a triphenylenylene group, a pyrenylene group, a chrysenylene group, a perylenylene group, a pentaphenylenylene group, a hexacenylenylene group, a pentacenylenylene group, a thiophenylenylene group, a furanylenylene group, a carbazolylenylene group, an indolylenylene group, an isoindolylenylene group, a benzofuranylenylene group, a benzothiophenylenylene group, a benzofuranylenylene group, a dibenzothiophenylenylene group, a benzocarbazolylenylene group, a dibenzocarbazolylenylene group, a dibenzosilolylenylene group, a pyridinylenylene group, an imidazolylenylene group, a pyrazolylenylene group, a thiazolylenylene group, an isothiazolylenylene group, an oxazolylenylene group, an isoxazolylenylene group, a thiadiazolylenylene group, an oxadiazolylenylene group, a pyrazinylenylene group, a pyrimidinylenylene group, a pyridazinylenylene group, a triazinylenylene group, a quinolinylene group, an isoquinolinylene group, a benzoquinolinylene group, a phthalazinylenylene group, a naphthyridinylenylene group, a quinoxalinylenylene group, a quinazolinylenylene group, a cinnolinylenylene group, a phenanthridinylenylene group, an acridinylenylene group, a phenanthrolinylenylene group, a phenazinylenylene group, a benzimidazolylenylene group, an isobenzothiazolylenylene group, a benzoxazolylenylene group, an isobenzoxazolylenylene group, a triazolylenylene group, a tetrazolylenylene group, an imidazopyridinylenylene group, an imidazopyrimidinylenylene group, and an azacarbazolylenylene group; and

[0360] a phenylene group, a naphthylene group, a fluorenylene group, a spiro-bifluorenylene group, a benzofluorenylene group, a dibenzofluorenylene group, a phenanthrenylene group, an anthracenylenylene group, a fluoranthenylenylene group, a triphenylenylene group, a pyrenylene group, a chrysenylene group, a perylenylene group, a pentaphenylenylene group, a hexacenylenylene group, a pentacenylenylene group, a thiophenylenylene group, a furanylenylene group, a carbazolylenylene group, an indolylenylene group, an isoindolylenylene group, a benzofuranylenylene group, a benzothiophenylenylene group, a benzofuranylenylene group, a dibenzothiophenylenylene group, a benzocarbazolylenylene group, a dibenzocarbazolylenylene group, a dibenzosilolylenylene group, a pyridinylenylene group, an imidazolylenylene group, a pyrazolylenylene group, a thiazolylenylene group, an isothiazolylenylene group, an oxazolylenylene group, an isoxazolylenylene group, a thiadiazolylenylene group, an oxadiazolylenylene group, a pyrazinylenylene group, a pyrimidinylenylene group, a pyridazinylenylene group, a triazinylenylene group, a quinolinylene group, an isoquinolinylene group, a benzoquinolinylene group, a phthalazinylenylene group, a naphthyridinylenylene group, a quinoxalinylenylene group, a quinazolinylenylene group, a cinnolinylenylene group, a phenanthridinylenylene group, an acridinylenylene group, a phenanthrolinylenylene group, a phenazinylenylene group,

a benzimidazolylenylene group, an isobenzothiazolylenylene group, a benzoxazolylenylene group, an isobenzoxazolylenylene group, a triazolylenylene group, a tetrazolylenylene group, an imidazopyridinylenylene group, an imidazopyrimidinylenylene group, and an azacarbazolylenylene group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazino group, a hydrazono group, a C₁-C₂₀ alkyl group, a C₁-C₂₀ alkoxy group, a phenyl group, a biphenyl group, a terphenyl group, a naphthyl group, a fluorenyl group, a spiro-bifluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a perylenyl group, a pentaphenyl group, a hexacenylenylene group, a pentacenylenylene group, a thiophenyl group, a furanyl group, a carbazolyl group, an indolyl group, an isoindolyl group, a benzofuranyl group, a benzothiophenyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, a dibenzosilolyl group, a pyridinyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a thiadiazolyl group, an oxadiazolyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a triazinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a phthalazinyl group, a naphthyridinyl group, a quinoxalinylenylene group, a quinazolinylenylene group, a cinnolinylenylene group, a phenanthridinyl group, an acridinyl group, a phenanthrolinyl group, a phenazinyl group, a benzimidazolyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, and an azacarbazolyl group, but embodiments of the present disclosure are not limited thereto.

[0361] In one or more embodiments, xe1 and xe613 in Formulae 601 and 601-1 may each independently be 0, 1, or 2.

[0362] In some embodiments, in Formulae 601 and 601-1, R₆₀₁ and R₆₁₁ to R₆₁₃ may each independently be selected from:

[0363] a phenyl group, a biphenyl group, a terphenyl group, a naphthyl group, a fluorenyl group, a spiro-bifluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a perylenyl group, a pentaphenyl group, a hexacenylenylene group, a pentacenylenylene group, a thiophenyl group, a furanyl group, a carbazolyl group, an indolyl group, an isoindolyl group, a benzofuranyl group, a benzothiophenyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, a dibenzosilolyl group, a pyridinyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a thiadiazolyl group, an oxadiazolyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a triazinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a phthalazinyl group, a naphthyridinyl group, a quinoxalinylenylene group, a quinazolinylenylene group, a cinnolinylenylene group, a phenanthridinyl group, an acridinyl group, a phenanthrolinyl group, a phenazinyl group, a benzimidazolyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetra-

zoyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, and an azacarbazolyl group;


[0364] a phenyl group, a biphenyl group, a terphenyl group, a naphthyl group, a fluorenyl group, a spiro-bifluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a perylenyl group, a pentaphenyl group, a hexacenyl group, a pentacenyl group, a thiophenyl group, a furanyl group, a carbazolyl group, an indolyl group, an isoindolyl group, a benzofuranyl group, a benzothiophenyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, a dibenzosilolyl group, a pyridinyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a thiadiazolyl group, an oxadiazolyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a triazinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a phthalazinyl group, a naphthyridinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a phenanthridinyl group, an acridinyl group, a phenanthrolinyl group, a phenazinyl group, a benzimidazolyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, and an azacarbazolyl group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazino group, a hydrazono group, a C₁-C₂₀ alkyl group, a C₁-C₂₀ alkoxy group, a phenyl group, a biphenyl group, a terphenyl group, a naphthyl group, a fluorenyl group, a spiro-bifluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a perylenyl group, a pentaphenyl group, a hexacenyl group, a pentacenyl group, a thiophenyl group, a furanyl group, a carbazolyl group, an indolyl group, an isoindolyl group, a benzofuranyl group, a benzothiophenyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, a dibenzosilolyl group, a pyridinyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a thiadiazolyl group, an oxadiazolyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a triazinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a phthalazinyl group, a naphthyridinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a phenanthridinyl group, an acridinyl group, a phenanthrolinyl group, a phenazinyl group, a benzimidazolyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, and an azacarbazolyl group; and

[0365] —S(=O)₂(Q₆₀₁) and —P(=O)(Q₆₀₁)(Q₆₀₂),


[0366] wherein Q₆₀₁ and Q₆₀₂ may each independently be the same as described herein.

[0367] The electron transport region may include at least one compound selected from Compounds ET1 to ET36, but embodiments of the present disclosure are not limited thereto:


ET1



ET2




ET3




-continued

ET4




-continued


ET8




ET5




ET6



ET7




ET9




-continued

ET10




-continued


ET13




ET11




ET14




ET12



ET15




-continued




ET16

-continued




ET19


ET17




ET18



ET20




ET21




-continued

ET22




-continued


ET25




ET23




ET26



ET24




ET27




-continued

ET28




-continued


ET31




ET29




ET32






ET30




ET33





-continued




ET34

Alq₃

ET35




TAZ



NTAZ

ET36



TSP01

[0368] In some embodiments, the electron transport region may include at least one compound selected from 2,9-dimethyl-4,7-diphenyl-1,10-phenanthroline (BCP), 4,7-diphenyl-1,10-phenanthroline (Bphen), Alq₃, BAlq, 3-(biphenyl-4-yl)-5-(4-tert-butylphenyl)-4-phenyl-4H-1,2,4-triazole (TAZ), NTAZ, and diphenyl(4-(triphenylsilyl)phenyl)phosphine oxide (TSP01):

[0369] The thicknesses of the buffer layer, the hole blocking layer, and/or the electron control layer may each independently be about 20 Å to about 1,000 Å, and in some embodiments, about 30 Å to about 300 Å. When the thicknesses of the buffer layer, the hole blocking layer and/or


the electron control layer are within these ranges, excellent hole blocking characteristics and/or excellent electron controlling characteristics may be obtained without a substantial increase in driving voltage.

[0370] The thickness of the electron transport layer may be about 100 Å to about 1,000 Å, and in some embodiments, about 150 Å to about 500 Å. When the thickness of the electron transport layer is within these ranges, excellent electron transport characteristics may be obtained without a substantial increase in driving voltage.


[0371] The electron transport region (for example, the electron transport layer in the electron transport region) may further include, in addition to the materials described above, a material including a metal.

[0372] The material including the metal may include at least one selected from an alkali metal complex and an alkaline earth metal complex. The alkali metal complex may include a metal ion selected from a lithium (Li) ion, a sodium (Na) ion, a potassium (K) ion, a rubidium (Rb) ion, and a cesium (Cs) ion. The alkaline earth metal complex may include a metal ion selected from a beryllium (Be) ion, a magnesium (Mg) ion, a calcium (Ca) ion, a strontium (Sr) ion, and a barium (Ba) ion. Each ligand coordinated with the metal ion in the alkali metal complex and/or with the metal ion of the alkaline earth metal complex may independently be selected from a hydroxyquinoline, a hydroxyisoquinoline, a hydroxybenzoquinoline, a hydroxyacridine, a hydroxyphenanthridine, a hydroxyphenyloxazole, a hydroxyphenylthiazole, a hydroxydiphenyl oxadiazole, a hydroxydiphenyl thiadiazole, a hydroxyphenyl pyridine, a hydroxyphenyl benzimidazole, a hydroxyphenyl benzothiazole, a bipyridine, a phenanthroline, and a cyclopentadiene, but embodiments of the present disclosure are not limited thereto.

[0373] For example, the material including metal may include a Li complex. The Li complex may include, e.g., Compound ET-D1 (lithium 8-hydroxyquinolate, LiQ) and/or Compound ET-D2:



ET-D1



ET-D2

[0374] The electron transport region may include an electron injection layer that facilitates injection of electrons from the second electrode **190**. The electron injection layer may be in direct contact with the second electrode **190**.

[0375] The electron injection layer may have: i) a single-layered structure including a single layer including a single material, ii) a single-layered structure including a single layer including a plurality of different materials, or iii) a multi-layered structure having a plurality of layers, each including a plurality of different materials.

[0376] The electron injection layer may include an alkali metal, an alkaline earth metal, a rare earth metal, an alkali metal compound, an alkaline earth metal compound, a rare earth metal compound, an alkali metal complex, an alkaline earth metal complex, a rare earth metal complex, or a combination thereof.

[0377] The alkali metal may be selected from Li, Na, K, Rb, and Cs. In some embodiments, the alkali metal may be Li, Na, or Cs. In one or more embodiments, the alkaline earth metal may be Li or Cs, but embodiments of the present disclosure are not limited thereto.

[0378] The alkaline earth metal may be selected from Mg, Ca, Sr, and Ba.

[0379] The rare earth metal may be selected from Sc, Y, Ce, Tb, Yb, and Gd.

[0380] The alkali metal compound, the alkaline earth metal compound, and the rare earth metal compound may each independently be selected from oxides and halides (e.g., fluorides, chlorides, bromides, and/or iodines) of the alkali metal, the alkaline earth metal, and the rare earth metal, respectively.

[0381] The alkali metal compound may be selected from alkali metal oxides (such as Li₂O, Cs₂O, and/or K₂O) and alkali metal halides (such as LiF, NaF, CsF, KF, LiI, NaI, CsI, KI, and/or RbI). In some embodiments, the alkali metal compound may be selected from LiF, Li₂O, NaF, LiI, NaI, CsI, and KI, but embodiments of the present disclosure are not limited thereto.

[0382] The alkaline earth-metal compound may be selected from alkaline earth-metal compounds (such as BaO, SrO, CaO, Ba_xSr_{1-x}O (wherein 0 < x < 1), and/or Ba_xCa_{1-x}O (wherein 0 < x < 1)). In some embodiments, the alkaline earth metal compound may be selected from BaO, SrO, and CaO, but embodiments of the present disclosure are not limited thereto.

[0383] The rare earth metal compound may be selected from YbF₃, ScF₃, ScO₃, Y₂O₃, Ce₂O₃, GdF₃, and TbF₃. In some embodiments, the rare earth metal compound may be selected from YbF₃, ScF₃, TbF₃, YbI₃, ScI₃, and TbI₃, but embodiments of the present disclosure are not limited thereto.

[0384] The alkali metal complex, the alkaline earth metal complex, and the rare earth metal complex may include ions of the above-described alkali metal, alkaline earth metal, and rare earth metal, respectively. Each ligand coordinated with the metal ion of the alkali metal complex, the alkaline earth metal complex, and/or the rare earth metal complex may independently be selected from a hydroxyquinoline, a hydroxyisoquinoline, a hydroxybenzoquinoline, a hydroxyacridine, a hydroxyphenanthridine, a hydroxyphenyloxazole, a hydroxyphenylthiazole, a hydroxydiphenyl oxadiazole, a hydroxydiphenyl thiadiazole, a hydroxyphenyl pyridine, a hydroxyphenyl benzimidazole, a hydroxyphenyl benzothiazole, a bipyridine, a phenanthroline, and a cyclopentadiene, but embodiments of the present disclosure are not limited thereto.

[0385] The electron injection layer may include (e.g., consist of) an alkali metal, an alkaline earth metal, a rare

earth metal, an alkali metal compound, an alkaline earth metal compound, a rare earth metal compound, an alkali metal complex, an alkaline earth metal complex, a rare earth metal complex, or a combination thereof, as described above. In some embodiments, the electron injection layer may further include an organic material. When the electron injection layer further includes an organic material, the alkali metal, the alkaline earth metal, the rare earth metal, the alkali metal compound, the alkaline earth metal compound, the rare earth metal compound, the alkali metal complex, the alkaline earth metal complex, the rare earth metal complex, or combination thereof may be homogeneously or non-homogeneously dispersed in a matrix including the organic material.

[0386] The thickness of the electron injection layer may be about 1 Å to about 100 Å, and in some embodiments, about 3 Å to about 90 Å. When the thickness of the electron injection layer is within these ranges, excellent electron injection characteristics may be obtained without a substantial increase in driving voltage.

Second Electrode 190

[0387] The second electrode 190 may be on the organic layer 150. In some embodiments, the second electrode 190 may be a cathode that is an electron injection electrode. In this embodiment, a material for forming the second electrode 190 may be a material having a low work function (such as a metal, an alloy, an electrically conductive compound, and/or a combination thereof).

[0388] The second electrode 190 may include at least one selected from lithium (Li), silver (Ag), magnesium (Mg), aluminum (Al), aluminum-lithium (Al—Li), calcium (Ca), magnesium-indium (Mg—In), magnesium-silver (Mg—Ag), ITO, and IZO, but embodiments of the present disclosure are not limited thereto. The second electrode 190 may be a transmissive electrode, a semi-transmissive electrode, or a reflective electrode.

[0389] The second electrode 190 may have a single-layered structure, or a multi-layered structure including two or more layers.

Description of FIGS. 2 to 4

[0390] Referring to FIG. 2, an organic light-emitting device 20 includes a first capping layer 210, the first electrode 110, the organic layer 150, and the second electrode 190, wherein the layers are sequentially stacked in this stated order. Referring to FIG. 3, an organic light-emitting device 30 includes the first electrode 110, the organic layer 150, the second electrode 190, and a second capping layer 220, wherein the layers are sequentially stacked in this stated order. Referring to FIG. 4, an organic light-emitting device 40 includes the first capping layer 210, the first electrode 110, the organic layer 150, the second electrode 190, and the second capping layer 220, wherein the layers are stacked in this stated order.

[0391] The first electrode 110, the organic layer 150, and the second electrode 190 illustrated in FIGS. 2 to 4 may be substantially the same as those illustrated in FIG. 1.

[0392] In the organic light-emitting devices 20 and 40, light emitted from the emission layer in the organic layer 150 may pass through the first electrode 110 (which may be a semi-transmissive electrode or a transmissive electrode) and the first capping layer 210 to the outside. In the organic

light-emitting devices 30 and 40, light emitted from the emission layer in the organic layer 150 may pass through the second electrode 190 (which may be a semi-transmissive electrode or a transmissive electrode) and the second capping layer 220 to the outside.


[0393] The first capping layer 210 and the second capping layer 220 may improve the external luminescent efficiency based on the principle of constructive interference.

[0394] The first capping layer 210 and the second capping layer 220 may each independently be a capping layer including an organic material, an inorganic capping layer including an inorganic material, or a composite capping layer including an organic material and an inorganic material.


[0395] At least one of the first capping layer 210 and the second capping layer 220 may each independently include at least one material selected from carbocyclic compounds, heterocyclic compounds, amine-based compounds, porphyrin derivatives, phthalocyanine derivatives, naphthalocyanine derivatives, alkali metal complexes, and alkaline earth metal complexes. The carbocyclic compound, the heterocyclic compound, and the amine-based compound may optionally be substituted with a substituent containing at least one element selected from O, N, S, Se, Si, F, Cl, Br, and I. In some embodiments, at least one of the first capping layer 210 and the second capping layer 220 may each independently include an amine-based compound.

[0396] In one or more embodiments, at least one of the first capping layer 210 and the second capping layer 220 may each independently include a compound represented by Formula 201 or a compound represented by 202.

[0397] In one or more embodiments, at least one of the first capping layer 210 and the second capping layer 220 may each independently include a compound selected from Compounds HT28 to HT33 and Compound CP1 to CP5, but embodiments of the present disclosure are not limited thereto:



-continued



[0398] Hereinbefore, the organic light-emitting device has been described with reference to FIGS. 1 to 4, but embodiments of the present disclosure are not limited thereto.

[0399] The layers constituting the hole transport region, the emission layer, and the layers constituting the electron transport region may each be formed in a set or predetermined region using one or more suitable methods available in the art (such as vacuum deposition, spin coating, casting, Langmuir-Blodgett (LB) deposition, ink-jet printing, laser printing, and laser-induced thermal imaging).

[0400] When layers constituting the hole transport region, the emission layer, and the layers constituting the electron transport region are each independently formed by vacuum deposition, the vacuum deposition may be performed at a deposition temperature of about 100° C. to about 500° C., at a vacuum degree of about 10⁻⁸ torr to about 10⁻³ torr, and at a deposition rate of about 0.01 Angstroms per second (Å/sec) to about 100 Å/sec, depending on the material to be included in each layer and the structure of each layer to be formed.

[0401] When layers constituting the hole transport region, the emission layer, and the layers constituting the electron transport region are each independently formed by spin coating, the spin coating may be performed at a coating rate of about 2,000 revolutions per minute (rpm) to about 5,000 rpm and at a heat treatment temperature of about 80° C. to 200° C., depending on the material to be included in each layer and the structure of each layer to be formed.

General Definitions of Substituents

[0402] The term “first-row transition metal” as used herein refers to any of the metallic elements belonging to Period 4 and the first row of the d-block of the Periodic Table of Elements. Examples thereof include scandium (Sc), titanium (Ti), vanadium (V), chromium (Cr), manganese (Mn), iron (Fe), cobalt (Co), nickel (Ni), copper (Cu), and zinc (Zn).

[0403] The term “second-row transition metal” as used herein refers to any of the metallic elements belonging to Period 5 and the second row of the d-block of the Periodic Table of Elements. Examples thereof include yttrium (Y), zirconium (Zr), niobium (Nb), molybdenum (Mo), technetium (Tc), ruthenium (Ru), rhodium (Rh), palladium (Pd), silver (Ag), and cadmium (Cd).

[0404] The term “third-row transition metal” as used herein refers to any of the metallic elements belonging to Period 6 and the third row of the d-block/first row of f-block of the Periodic Table of Elements. Examples thereof include lanthanum (La), samarium (Sm), europium (Eu), terbium (Tb), thulium (Tm), ytterbium (Yb), lutetium (Lu), hafnium (Hf), tantalum (Ta), tungsten (W), rhenium (Re), osmium (Os), iridium (Ir), platinum (Pr), gold (Au), and mercury (Hg).

[0405] The term “C₁-C₆₀ alkyl group” as used herein refers to a linear or branched aliphatic hydrocarbon monovalent group including 1 to 60 carbon atoms. Non-limiting examples thereof include a methyl group, an ethyl group, a propyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, a pentyl group, an iso-amyl group, and a hexyl group. The term “C₁-C₆₀ alkylene group” as used herein refers to a divalent group having substantially the same structure as the C₁-C₆₀ alkyl group.

[0406] The term “C₂-C₆₀ alkenyl group” as used herein refers to a hydrocarbon group including at least one carbon-carbon double bond in the middle or at the terminus of the C₂-C₆₀ alkyl group. Non-limiting examples thereof include an ethenyl group, a propenyl group, and a butenyl group. The term “C₂-C₆₀ alkenylene group” as used herein refers to a divalent group having substantially the same structure as the C₂-C₆₀ alkenyl group.

[0407] The term “C₂-C₆₀ alkynyl group” as used herein refers to a hydrocarbon group including at least one carbon-carbon triple bond in the middle or at the terminus of the C₂-C₆₀ alkyl group. Non-limiting examples thereof include an ethynyl group and a propynyl group. The term “C₂-C₆₀ alkynylene group” as used herein refers to a divalent group having substantially the same structure as the C₂-C₆₀ alkynyl group.

[0408] The term “C₁-C₆₀ alkoxy group” as used herein refers to a monovalent group represented by —OA₁₀₁ (wherein A₁₀₁ is a C₁-C alkyl group). Non-limiting examples thereof include a methoxy group, an ethoxy group, and an isopropoxy group.

[0409] The term “C₃-C₁₀ cycloalkyl group” as used herein refers to a monovalent saturated hydrocarbon monocyclic group including 3 to 10 carbon atoms. Non-limiting examples thereof include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, and a cycloheptyl group. The term “C₃-C₁₀ cycloalkylene group” as used herein refers to a divalent group having substantially the same structure as the C₃-C₁₀ cycloalkyl group.

[0410] The term “C₁-C₁₀ heterocycloalkyl group” as used herein refers to a monovalent monocyclic group including at least one heteroatom selected from N, O, Si, P, and S as a ring-forming atom, and 1 to 10 carbon atoms. Non-limiting examples thereof include a 1,2,3,4-oxatriazolindinyl group, a tetrahydrofuran group, and a tetrahydrothiophenyl group. The term “C₁-C₁₀ heterocycloalkylene group” as used herein refers to a divalent group having substantially the same structure as the C₁-C₁₀ heterocycloalkyl group.

[0411] The term “C₃-C₁₀ cycloalkenyl group” as used herein refers to a monovalent monocyclic group including 3 to 10 carbon atoms and at least one double bond in its ring, and which is not aromatic. Non-limiting examples thereof include a cyclopentenyl group, a cyclohexenyl group, and a cycloheptenyl group. The term “C₃-C₁₀ cycloalkenylene group” as used herein refers to a divalent group having substantially the same structure as the C₃-C₁₀ cycloalkenyl group.

[0412] The term “C₁-C₁₀ heterocycloalkenyl group” as used herein refers to a monovalent monocyclic group including at least one heteroatom selected from N, O, Si, P, and S as a ring-forming atom, 1 to 10 carbon atoms, and at least one double bond in its ring. Non-limiting examples of the C₁-C₁₀ heterocycloalkenyl group include a 4,5-dihydro-1,2,3,4-oxatriazolyl group, a 2,3-dihydrofuran group, and a 2,3-dihydrothiophenyl group. The term “C₁-C₁₀ heterocycloalkylene group” as used herein refers to a divalent group having substantially the same structure as the C₁-C₁₀ heterocycloalkyl group.

[0413] The term “C₆-C₆₀ aryl group” as used herein refers to a monovalent group having a carbocyclic aromatic system including 6 to 60 carbon atoms. The term “C₆-C₆₀ arylene group” as used herein refers to a divalent group having a carbocyclic aromatic system including 6 to 60 carbon atoms. Non-limiting examples of the C₆-C₆₀ aryl group include a phenyl group, a naphthyl group, an anthracenyl group, a phenanthrenyl group, a pyrenyl group, and a chrysenyl group. When the C₆-C₆₀ aryl group and the C₆-C₆₀ arylene group each independently include two or more rings, the respective rings may be fused (e.g., combined).

[0414] The term “C₁-C₆₀ heteroaryl group” as used herein refers to a monovalent group having a heterocyclic aromatic system including at least one heteroatom selected from N, O, Si, P, and S as a ring-forming atom, and 1 to 1 carbon atoms. The term “C₁-C₆₀ heteroarylene group” as used herein refers to a divalent group having a heterocyclic aromatic system including at least one heteroatom selected from N, O, Si, P, and S as a ring-forming atom and 1 to 60 carbon atoms. Non-limiting examples of the C₁-C₆₀ heteroaryl group include a pyridinyl group, a pyrimidinyl group, a pyrazinyl group, a pyridazinyl group, a triazinyl group, a quinolinyl group, and an isoquinolinyl group. When the C₁-C₆₀ heteroaryl group and the C₁-C₆₀ heteroarylene group each independently include two or more rings, the respective rings may be fused.

[0415] The term “C₆-C₆₀ aryloxy group” as used herein is represented by —OA₁₀₂ (wherein A₁₀₂ is a C₆-C₆₀ aryl group). The term “C₆-C₆₀ arylthio group” as used herein is represented by —SA₁₀₃ (wherein A₁₀₃ is a C₆-C₆₀ aryl group).

[0416] The term “C₁-C₆₀ heteroaryloxy group” as used herein refers to a monovalent group represented by —OA₁₀₄ (wherein A₁₀₄ is a C₁-C₆₀ heteroaryl group). The term “C₁-C₆₀ heteroarylthio group” as used herein refers to a monovalent group represented by —SA₁₀₅ (wherein A₁₀₅ is a C₁-C₆₀ heteroaryl group).

[0417] The term “monovalent non-aromatic condensed polycyclic group” as used herein refers to a monovalent group that has two or more condensed rings and includes only carbon atoms as ring forming atoms (e.g., 8 to 60 carbon atoms), wherein the entire molecular structure is

non-aromatic. A non-limiting example of the monovalent non-aromatic condensed polycyclic group includes a fluorenyl group. The term “divalent non-aromatic condensed polycyclic group” as used herein refers to a divalent group having substantially the same structure as the monovalent non-aromatic condensed polycyclic group.

[0418] The term “monovalent non-aromatic condensed heteropolycyclic group” as used herein refers to a monovalent group that has two or more condensed rings and includes at least one heteroatom selected from N, O, Si, P, and S, in addition to carbon atoms (e.g., 1 to 60 carbon atoms) as ring-forming atoms, wherein the entire molecular structure is non-aromatic. A non-limiting example of the monovalent non-aromatic condensed heteropolycyclic group is a carbazolyl group. The term “divalent non-aromatic condensed heteropolycyclic group” as used herein refers to a divalent group having substantially the same structure as the monovalent non-aromatic condensed heteropolycyclic group.

[0419] The term “C₅-C₆₀ carbocyclic group” as used herein refers to a monocyclic or polycyclic group having 5 to 60 carbon atoms only as ring-forming atoms. The C₅-C₆₀ carbocyclic group may be an aromatic carbocyclic group or a non-aromatic carbocyclic group. The term “C₅-C₆₀ carbocyclic group” as used herein may refer to a ring (e.g., a benzene group), a monovalent group (e.g., a phenyl group), or a divalent group (e.g., a phenylene group). Also, depending on the number of substituents connected to the C₅-C₆₀ carbocyclic group, the C₅-C₆₀ carbocyclic group may be a trivalent group or a quadrivalent group.

[0420] The term “C₁-C₆₀ heterocyclic group” as used herein refers to a group having substantially the same structure as the C₅-C₆₀ carbocyclic group, except that at least one heteroatom selected from N, O, Si, P, and S is used as a ring-forming atom, in addition to carbon atoms (e.g., 1 to 60 carbon atoms).

[0421] In the present specification, at least one substituent of the substituted C₅-C₆₀ carbocyclic group, the substituted C₁-C₆₀ heterocyclic group, the substituted C₃-C₁₀ cycloalkylene group, the substituted C₁-C₁₀ heterocycloalkylene group, the substituted C₃-C₁₀ cycloalkenylene group, the substituted C₁-C₁₀ heterocycloalkylene group, the substituted C₆-C₆₀ arylene group, the substituted C₁-C₆₀ heteroarylene group, the substituted divalent non-aromatic condensed polycyclic group, the substituted divalent non-aromatic condensed heteropolycyclic group, the substituted C₁-C₆₀ alkyl group, the substituted C₂-C₆₀ alkenyl group, the substituted C₂-C₆₀ alkynyl group, the substituted C₁-C₆₀ alkoxy group, the substituted C₃-C₁₀ cycloalkyl group, the substituted C₁-C₁₀ heterocycloalkyl group, the substituted C₃-C₁₀ cycloalkenyl group, the substituted C₁-C₁₀ heterocycloalkenyl group, the substituted C₆-C₆₀ aryl group, the substituted C₆-C₆₀ aryloxy group, the substituted C₆-C₆₀ arylthio group, the substituted C₁-C₆₀ heteroaryl group, the substituted C₁-C₆₀ heteroaryloxy group, the substituted C₁-C₆₀ heteroarylthio group, the substituted monovalent non-aromatic condensed polycyclic group, and the substituted monovalent non-aromatic condensed heteropolycyclic group may be selected from:

[0422] deuterium (-D), —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazino group, a hydrazono group, a C₁-C₆₀ alkyl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, and a C₁-C₆₀ alkoxy group;

[0423] a C₁-C₆₀ alkyl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, and a C₁-C₆₀ alkoxy group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazino group, a hydrazono group, a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocy-

cloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₁-C₆₀ heteroaryl group, a C₁-C₆₀ heteroaryloxy group, a C₁-C₆₀ heteroarylthio group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —Si(Q₁₁)(Q₁₂)(Q₁₃), —N(Q₁₁)(Q₁₂), —B(Q₁₁)(Q₁₂), —C(=O)(Q₁₁), —S(=O)₂(Q₁₁), and —P(=O)(Q₁₁)(Q₁₂);

[0424] a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₁-C₆₀ heteroaryl group, a C₁-C₆₀ heteroaryloxy group, a C₁-C₆₀ heteroarylthio group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group;

[0425] a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₁-C₆₀ heteroaryl group, a C₁-C₆₀ heteroaryloxy group, a C₁-C₆₀ heteroarylthio group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazino group, a hydrazono group, a C₁-C₆₀ alkyl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, a C₁-C₆₀ alkoxy group, a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₁-C₆₀ heteroaryl group, a C₁-C₆₀ heteroaryloxy group, a C₁-C₆₀ heteroarylthio group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —Si(Q₂₁)(Q₂₂)(Q₂₃), —N(Q₂₁)(Q₂₂), —B(Q₂₁)(Q₂₂), —C(=O)(Q₂₁), —S(=O)₂(Q₂₁), and —P(=O)(Q₂₁)(Q₂₂); and

[0426] —Si(Q₃₁)(Q₃₂)(Q₃₃), —N(Q₃₁)(Q₃₂), —B(Q₃₁)(Q₃₂), —C(=O)(Q₃₁), —S(=O)₂(Q₃₁), and —P(=O)(Q₃₁)(Q₃₂);

[0427] wherein Q₁₁ to Q₁₃, Q₂₁ to Q₂₃, and Q₃₁ to Q₃₃ may each independently be selected from hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazino group, a hydrazono group, a C₁-C₆₀ alkyl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, a C₁-C₆₀ alkoxy group, a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₁-C₆₀ heteroaryl group, a C₁-C₆₀ heteroaryloxy group, a C₁-C₆₀ heteroarylthio group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, a C₁-C₆₀ alkyl group substituted with at least one selected from deuterium, —F, and a cyano group, a C₆-C₆₀ aryl group substituted with at least one selected from deuterium, —F, and a cyano group, a biphenyl group, and a terphenyl group.

[0428] The term “Ph” as used herein refers to a phenyl group. The term “Me” as used herein refers to a methyl group. The term “Et” as used herein refers to an ethyl group. The term “ter-Bu” or “But” as used herein refers to a tert-butyl group. The term “OMe” as used herein refers to a methoxy group.

[0429] The term “biphenyl group” as used herein refers to a phenyl group substituted with a phenyl group. For example, a “biphenyl group” may be a substituted phenyl group having a C₆-C₆₀ aryl group as a substituent.

[0430] The term “terphenyl group” as used herein refers to a phenyl group substituted with a biphenyl group. For

example, a “terphenyl group” may be a substituted phenyl group having a C₆-C₆₀ aryl group substituted with a C₆-C₆₀ aryl group as a substituent.




[0431] The symbols * and ** as used herein, unless defined otherwise, refer to a binding site to an adjacent atom in a corresponding formula.



[0432] Hereinafter, compounds and an organic light-emitting device according to embodiments of the present disclosure will be described in more detail with reference to Synthesis Examples and Examples. The wording “B was used instead of A” used in describing Synthesis Examples indicates that an identical number of molar equivalents of B was used in place of A.

EXAMPLES

Synthesis Example 1: Synthesis of Compound 1

[0433]





1) Synthesis of Intermediate 1-A

[0434] 11.8 grams (g) (50 millimoles (mmol)) of 1,4-dibromobenzene, 3.4 g (50 mmol) of pyrazole, 23 g (100 mmol) of tripotassium phosphate, 1.83 g (10 mmol) of iodocopper, and 1.17 g (10 mmol) of picolinic acid were added to a reaction vessel. The mixture was suspended in 100 milliliters (mL) of dimethylsulfoxide. The mixture was stirred at 160° C. for 24 hours. Once the reaction was complete, the mixture was allowed to cool to room temperature. Then, 300 mL of distilled water was added thereto, and an organic layer was extracted using ethyl acetate. The extracted organic layer was washed with saturated sodium chloride aqueous solution, followed by drying over sodium sulfate. The residue from which the solvent was removed was separated by column chromatography to thereby obtain 8.9 g (40 mmol) of Intermediate 1-A.

2) Synthesis of Intermediate 1-B

[0435] 8.9 g (40 mmol) of Intermediate 1-A was suspended in 100 mL of tetrahydrofuran. Then, the suspension was cooled to a temperature of -78° C. 19 mL of n-BuLi (2.5 M in hexane) solution was slowly added dropwise thereto, followed by stirring at the same temperature for 1 hour. Next, 5.0 g (48 mmol) of trimethyl borate was slowly added dropwise thereto, and the temperature of the mixture was

raised to room temperature. Then, the mixture was stirred for 12 more hours. Once the reaction was complete, the acidity of the reaction solution was adjusted to pH 5 using 2N HCl solution, followed by stirring for 30 minutes, and an organic layer was extracted using ethyl acetate. The extracted organic layer was washed with saturated sodium chloride aqueous solution, followed by drying over sodium sulfate. 6.4 g (34 mmol) of Intermediate 1-B from which the solvent was removed was obtained. Intermediate 1-B was used in the following reaction without further purification.

3) Synthesis of Intermediate 1-C

[0436] 6.4 g (34 mmol) of Intermediate 1-B, 5.5 g (17 mmol) of 2,2'-dibromodiphenylamine, 4.7 g (34 mmol) of potassium carbonate, and 390 mg (0.34 mmol) of tetrakis (phenylphosphine)palladium were added to a reaction vessel. The mixture was suspended in a mixture solution of 25 mL of tetrahydrofuran and 25 mL of water. The mixture was stirred at 120° C. for 24 hours. Once the reaction was complete, the mixture was allowed to cool to room temperature. Then, 100 mL of distilled water was added thereto, and an organic layer was extracted using ethyl acetate. The extracted organic layer was washed with saturated sodium chloride aqueous solution, followed by drying over sodium sulfate. The residue from which the solvent was removed was separated by column chromatography to thereby obtain 5.0 g (11 mmol) of Intermediate 1-C.

4) Synthesis of Intermediate 1-D





[0437] 5.0 g (11 mmol) of Intermediate 1-C was suspended in toluene. The suspension was cooled to a temperature of -78° C. 4.4 mL of n-BuLi (2.5 M in hexane) solution was slowly added dropwise thereto, followed by stirring at 0° C. for 1 hour. Next, 11.0 mL of trichloroboron (1.0 M in hexane) solution was slowly added dropwise thereto, followed by stirring at room temperature for 8 hours. Subsequently, the solvent was removed therefrom, and a suspension of 5.9 g (44 mmol) of trichloroaluminum, 3.1 g (22 mmol) of 2,2,6,6-tetramethyl piperidine, and 70 mL of o-dichlorobenzene was added dropwise thereto. Then, the mixture was stirred at a temperature of 160° C. for 12 hours, and 4.9 g (44 mmol) of 1,4-diazabicyclo[2.2.2]octane was added dropwise thereto. The solid precipitate was removed therefrom using a filter. The residue from which the solvent was removed was separated by column chromatography to thereby obtain 2.6 g (5.5 mmol) of Intermediate 1-D.

5) Synthesis of Compound 1

[0438] 2.6 g (5.5 mmol) of Intermediate 1-D, 2.3 g (5.5 mmol) of potassium tetrachloroplatinate, and 180 mg (0.6 mmol) of tetraammonium bromide were suspended in 110 mL of acetic acid, followed by stirring at a temperature of 120° C. for 72 hours. Once the reaction was complete, the mixture was allowed to cool to room temperature. Then, 100 mL of distilled water was added thereto, and a solid compound was filtered. The filtered solid compound was separated by column chromatography to thereby obtain 1.1 g (1.7 mmol) of Compound 1.

Synthesis Example 2: Synthesis of Compound 6


[0439]




[0440] Compound 6 was synthesized in substantially the same manner as in Synthesis Example 1, except that 3,5-dimethyl pyrazole was used instead of pyrazole.

Synthesis Example 3: Synthesis of Compound 11

[0441]





1) Synthesis of Intermediate 11-C

[0442] 11.8 g (50 mmol) of 1,4-dibromobenzene, 6.1 g (50 mmol) of 2-pyridineboronic acid, 13.8 g (100 mmol) of potassium carbonate, and 1.1 g (1.0 mmol) of tetrakis(phenylphosphine)palladium were added to a reaction vessel. The mixture was suspended in a mixture solution of 100 mL of tetrahydrofuran and 100 mL of water. The mixture was stirred at 120° C. for 24 hours. Once the reaction was complete, the mixture was allowed to cool to room temperature. Then, 300 mL of distilled water was added thereto, and an organic layer was extracted using ethyl acetate. The extracted organic layer was washed with saturated sodium chloride aqueous solution, followed by drying over sodium sulfate. The residue from which the solvent was removed was separated by column chromatography to thereby obtain 9.8 g (42 mmol) of Intermediate 11-C.

2) Synthesis of Intermediate 11-D

[0443] 9.8 g (42 mmol) of Intermediate 11-C was suspended in 100 mL of tetrahydrofuran. Then, the suspension was cooled to a temperature of -78° C. 20 mL of n-BuLi (2.5 M in hexane) solution was slowly added dropwise thereto, followed by stirring at the same temperature for 1 hour. Next, 5.2 g (50 mmol) of trimethyl borate was slowly added dropwise thereto, and the temperature of the mixture was raised to room temperature. Then, the mixture was stirred for 12 more hours. Once the reaction was complete, the acidity of the reaction solution was adjusted to pH 5 using 2N HCl solution, followed by stirring for 30 minutes. Once the reaction was complete, an organic layer was extracted using ethyl acetate. The extracted organic layer was washed with

saturated sodium chloride aqueous solution, followed by drying over sodium sulfate. 6.8 g (34 mmol) of Intermediate 11-D from which the solvent was removed was obtained. Intermediate 11-D was used in the following reaction without further purification.

3) Synthesis of Intermediate 11-E

[0444] 6.4 g (34 mmol) of Intermediate 1-B, 11.0 g (34 mmol) of 2,2'-dibromodiphenylamine, 9.4 g (68 mmol) of potassium carbonate, and 780 mg (0.68 mmol) of tetrakis(phenylphosphine)palladium were added to a reaction vessel. The mixture was suspended in a mixture solution of 50 mL of tetrahydrofuran and 50 mL of water. The mixture was stirred at 20° C. for 24 hours. Once the reaction was complete, the mixture was allowed to cool to room temperature. Then, 100 mL of distilled water was added thereto, and an organic layer was extracted using ethyl acetate. The extracted organic layer was washed with saturated sodium chloride aqueous solution, followed by drying over sodium sulfate. The residue from which the solvent was removed was separated by column chromatography to thereby obtain 6.6 g (17 mmol) of Intermediate 11-E.

4) Synthesis of Intermediate 11-F

[0445] 6.6 g (17 mmol) of Intermediate 11-E, 4.1 g (20.4 mmol) of Intermediate 11-D, 4.7 g (34 mmol) of potassium carbonate, and 390 mg (0.34 mmol) of tetrakis(phenylphosphine)palladium were added to a reaction vessel. The mixture was suspended in a mixture solution of 25 mL of tetrahydrofuran and 25 mL of water. The mixture was stirred at 120° C. for 24 hours. Once the reaction was complete, the

mixture was allowed to cool to room temperature. Then, 100 mL of distilled water was added thereto, and an organic layer was extracted using ethyl acetate. The extracted organic layer was washed with saturated sodium chloride aqueous solution, followed by drying over sodium sulfate. The residue from which the solvent was removed was separated by column chromatography to thereby obtain 5.5 g (11.9 mmol) of Intermediate 11-F.

5) Synthesis of Intermediate 11-G

[0446] 5.5 g (11.9 mmol) of Intermediate 11-F was suspended in toluene. The suspension was cooled to a temperature of -78°C . 4.8 mL of *n*-BuLi (2.5 M in hexane) solution was slowly added dropwise thereto, followed by stirring at 0°C for 1 hour. Next, 12.0 mL of trichloroboron (1.0 M in hexane) solution was slowly added dropwise thereto, followed by stirring at room temperature for 8 hours. Subsequently, the solvent was removed therefrom under vacuum, and a suspension of 6.4 g (48 mmol) of trichloroaluminum, 3.4 g (24 mmol) of 2,2,6,6-tetramethyl piperidine, and 80 mL of *o*-dichlorobenzene was added dropwise thereto. Then,


the mixture was stirred at a temperature of 160°C for 12 hours, and 5.3 g (48 mmol) of 1,4-diazabicyclo[2.2.2]octane was added dropwise thereto. The solid precipitate was removed therefrom using a filter. The residue from which the solvent was removed was separated by column chromatography to thereby obtain 2.4 g (5.1 mmol) of Intermediate 11-G.

6) Synthesis of Compound 11

[0447] 2.4 g (5.1 mmol) of Intermediate 11-G, 2.1 g (5.1 mmol) of potassium tetrachloroplatinate, and 160 mg (0.5 mmol) of tetraammonium bromide were suspended in 100 mL of acetic acid, followed by stirring at a temperature of 120°C for 72 hours. Once the reaction is complete, the mixture was allowed to cool to room temperature. Then, 100 mL of distilled water was added thereto, and a solid compound was filtered. The filtered solid compound was separated by column chromatography to thereby obtain 850 mg (1.3 mmol) of Compound 11.

Synthesis Example 4: Synthesis of Compound 16


[0448]




[0449] 780 mg (1.1 mmol) of Compound 16 was obtained in substantially the same manner as in Synthesis Example 3, except that Intermediate 6-B was used instead of Intermediate 1-B, and 4-methylpyridine-2-boronic acid was used instead of 2-pyridineboronic acid.

Synthesis Example 5: Synthesis of Compound 21

[0450]





1) Synthesis of Intermediate 21-C

[0451] 11.8 g (50 mmol) of 1,4-dibromobenzene, 5.9 g (50 mmol) of benzimidazole, 23 g (100 mmol) of tripotassium phosphate, 1.83 g (10 mmol) of iodocopper, and 1.17 g (10 mmol) of picolinic acid were added to a reaction vessel. The mixture was suspended in 100 mL of dimethylsulfoxide. The mixture was stirred at 160° C. for 24 hours. Once the reaction was complete, the mixture was allowed to cool to room temperature. Then, 300 mL of distilled water was added thereto, and an organic layer was extracted using ethyl acetate. The extracted organic layer was washed with saturated sodium chloride aqueous solution, followed by drying over sodium sulfate. The residue from which the solvent was removed was separated by column chromatography to thereby obtain 9.6 g (35 mmol) of Intermediate 21-C.

2) Synthesis of Intermediate 21-D

[0452] 9.6 g (35 mmol) of Intermediate 21-C was suspended in 100 mL of tetrahydrofuran. Then, the suspension was cooled to a temperature of -78° C. 19 mL of n-BuLi (2.5 M in hexane) solution was slowly added dropwise thereto, followed by stirring at the same temperature for 1 hour. Next, 4.3 g (42 mmol) of trimethyl borate was slowly added dropwise thereto, and the temperature of the mixture was raised to room temperature. Then, the mixture was stirred for 12 more hours. Once the reaction was complete, the acidity of the reaction solution was adjusted to pH 5 using 2N HCl solution, followed by stirring for 30 minutes. Once the reaction was complete, an organic layer was extracted using ethyl acetate. The extracted organic layer was washed with saturated sodium chloride aqueous solution, followed by drying over sodium sulfate. The solvent was removed to obtain 7.2 g (30 mmol) of Intermediate 21-C. Intermediate 21-C was used in the following reaction without any further purification.

3) Synthesis of Intermediate 21-F

[0453] 6.6 g (17 mmol) of Intermediate 11-E, 4.9 g (20.4 mmol) of Intermediate 21-D, 4.7 g (34 mmol) of potassium carbonate, and 390 mg (0.34 mmol) of tetrakis(phenylphosphine)palladium were added to a reaction vessel. The mixture was suspended in a mixture solution of 25 mL of tetrahydrofuran and 25 mL of water. The mixture was stirred at 120° C. for 24 hours. Once the reaction was complete, the

mixture was allowed to cool to room temperature. Then, 100 mL of distilled water was added thereto, and an organic layer was extracted using ethyl acetate. The extracted organic layer was washed with saturated sodium chloride aqueous solution, followed by drying over sodium sulfate. The residue from which the solvent was removed was separated by column chromatography to thereby obtain 5.6 g (11.1 mmol) of Intermediate 21-F.

4) Synthesis of Intermediate 21-G

[0454] 5.6 g (11.1 mmol) of Intermediate 21-F was suspended in toluene. The suspension was cooled to a temperature of -78° C. 5 mL of n-BuLi (2.5 M in hexane) solution was slowly added dropwise thereto, followed by stirring at 0° C. for 1 hour. Next, 11.2 mL of trichloroboron (1.0 M in hexane) solution was slowly added dropwise thereto, followed by stirring at room temperature for 8 hours. Subsequently, the solvent was removed therefrom under vacuum, and a suspension of 6.0 g (45 mmol) of trichloroaluminum, 3.2 g (22 mmol) of 2,2,6,6-tetramethyl piperidine, and 75 mL of o-dichlorobenzene was added dropwise thereto. Then, the mixture was stirred at a temperature of 160° C. for 12 hours, and 4.9 g (45 mmol) of 1,4-diazabicyclo[2.2.2]octane was added dropwise thereto. The solid precipitate was removed therefrom using a filter. The residue from which the solvent was removed was separated by column chromatography to thereby obtain 2.6 g (5.0 mmol) of Intermediate 21-G.

5) Synthesis of Intermediate 21-H

[0455] 5.6 g (11.1 mmol) of Intermediate 21-G and 3.2 g (22.2 mmol) of iodized methyl were suspended in 110 mL of toluene, followed by stirring at a temperature of 110° C. for 12 hours. Once the reaction was complete, the mixture was cooled to room temperature. Then, the solid compound was filtered and washed using ethyl ether. The result was then dried to obtain 6.9 g (10.5 mmol) of Intermediate 21-H.

6) Synthesis of Intermediate 21-I

[0456] 6.9 g (10.5 mmol) of Intermediate 21-H was suspended in a mixture solution of 55 mL of methyl alcohol and 55 mL of water. Subsequently, 2.6 g (15.8 mmol) of ammonium hexafluorophosphate was added dropwise thereto, followed by stirring at room temperature for 12 hours. Once




the reaction was complete, the solid compound was filtered and washed using ethyl ether. The result was then dried to obtain 6.3 g (9.5 mmol) of Intermediate 21-1.

7) Synthesis of Compound 21

[0457] 6.3 g (9.5 mmol) of Intermediate 21-1, 3.9 g (10.5 mmol) of dichloro(1,5-cyclooctadiene)platinum, and 1.6 g (19.0 mmol) of sodium acetate were suspended in 100 mL of dioxane. The mixture was stirred at 110° C. for 24 hours. Once the reaction was complete, the mixture was allowed to cool to room temperature. Then, 200 mL of distilled water was added thereto, and an organic layer was extracted using ethyl acetate. The extracted organic layer was washed with saturated sodium chloride aqueous solution, followed by drying over sodium sulfate. The residue from which the solvent was removed was separated by column chromatography to thereby obtain 2.2 g (3.1 mmol) of Compound 21.

Synthesis Example 6: Synthesis of Compound 26


[0458]



[0459] 1.9 g (2.5 mmol) of Compound 26 was obtained in substantially the same manner as in Synthesis Example 5, except that Intermediate 16-E was used instead of Intermediate 11-E.

Synthesis Example 7: Synthesis of Compound 31

[0460]



1) Synthesis of Intermediate 31-C

[0461] 11.8 g (50 mmol) of 1,4-dibromobenzene, 3.5 g (50 mmol) of 1H-1,2,3-triazole, 23 g (100 mmol) of tripotassium phosphate, 1.83 g (10 mmol) of iodocopper, and 1.17 g (10 mmol) of picolinic acid were added to a reaction vessel. The mixture was suspended in 100 mL of dimethylsulfoxide. The mixture was stirred at 160° C. for 24 hours. Once the reaction was complete, the mixture was allowed to cool to room temperature. Then, 300 mL of distilled water was added thereto, and an organic layer was extracted using ethyl acetate. The extracted organic layer was washed with saturated sodium chloride aqueous solution, followed by drying over sodium sulfate. The residue from which the

solvent was removed was separated by column chromatography to thereby obtain 8.7 g (39 mmol) of Intermediate 31-C.

2) Synthesis of Intermediate 31-D

[0462] 8.7 g (39 mmol) of Intermediate 31-C was suspended in 100 mL of tetrahydrofuran. Then, the suspension

was cooled to a temperature of -78° C. 19 mL of n-BuLi (2.5 M in hexane) solution was slowly added dropwise thereto, followed by stirring at the same temperature for 1 hour. Next, 4.8 g (48 mmol) of trimethyl borate was slowly added dropwise thereto, and the temperature of the mixture was raised to room temperature. Then, the mixture was stirred for 12 more hours. Once the reaction was complete, the acidity of the reaction solution was adjusted to pH 5 using 2N HCl solution, followed by stirring for 30 minutes. Once the reaction was complete, an organic layer was extracted using ethyl acetate. The extracted organic layer was washed with saturated sodium chloride aqueous solution, followed by drying over sodium sulfate. The solvent was removed to

obtain 6.2 g (33 mmol) of Intermediate 31-D. Intermediate 31-D was used in the following reaction without further purification.

3) Synthesis of Intermediate 31-F

[0463] 6.6 g (17 mmol) of Intermediate 11-E, 3.9 g (20.4 mmol) of Intermediate 31-D, 4.7 g (34 mmol) of potassium carbonate, and 390 mg (0.34 mmol) of tetrakis(phenylphosphine)palladium were added to a reaction vessel. The mixture was suspended in a mixture solution of 25 mL of tetrahydrofuran and 25 mL of water. The mixture was stirred at 120° C. for 24 hours. Once the reaction was complete, the mixture was allowed to cool to room temperature. Then, 100 mL of distilled water was added thereto, and an organic layer was extracted using ethyl acetate. The extracted organic layer was washed with saturated sodium chloride aqueous solution, followed by drying over sodium sulfate. The residue from which the solvent was removed was separated by column chromatography to thereby obtain 5.3 g (11.6 mmol) of Intermediate 31-F.

4) Synthesis of Intermediate 31-G

[0464] 5.3 g (11.6 mmol) of Intermediate 31-F was suspended in toluene. The suspension was cooled to a temperature of -78° C. 4.7 mL of n-BuLi (2.5 M in hexane) solution was slowly added dropwise thereto, followed by stirring at 0° C. for 1 hour. Next, 11.7 mL of trichloroboron (1.0 M in



hexane) solution was slowly added dropwise thereto, followed by stirring at room temperature for 8 hours. Subsequently, the solvent was removed therefrom under vacuum, and a suspension of 6.3 g (48 mmol) of trichloroaluminum, 3.5 g (24 mmol) of 2,2,6,6-tetramethyl piperidine, and 80 mL of o-dichlorobenzene was added dropwise thereto. Then, the mixture was stirred at a temperature of 160° C. for 12 hours, and 5.3 g (48 mmol) of 1,4-diazabicyclo[2.2.2]octane was added dropwise thereto. The solid precipitate was removed therefrom using a filter. The residue from which the solvent was removed was separated by column chromatography to thereby obtain 2.1 g (4.6 mmol) of Intermediate 31-G.


5) Synthesis of Compound 31

[0465] 2.1 g (4.6 mmol) of Intermediate 31-G, 1.9 g (4.6 mmol) of potassium tetrachloroplatinate, and 160 mg (0.5 mmol) of tetraammonium bromide were suspended in 100 mL of acetic acid, followed by stirring at a temperature of 120° C. for 72 hours. Once the reaction was complete, the mixture was allowed to cool to room temperature. Then, 100 mL of distilled water was added thereto, and a solid compound was filtered. The filtered solid compound was separated by column chromatography to thereby obtain 740 mg (1.1 mmol) of Compound 31.

Synthesis Example 8: Synthesis of Compound 36

[0466]





[0467] 1.0 g (1.6 mmol) of Compound 36 was obtained in substantially the same manner as in Synthesis Example 7, except that 2H-1,2,3-triazole was used instead of ¹H-1,2,3-triazole.

[0468] The compounds synthesized in Synthesis Examples 1 to 8 were identified by ¹H nuclear magnetic resonance (NMR) and mass spectroscopy/fast atom bombardment (MS/FAB). The results thereof are shown in Table 1.

[0469] Methods of synthesizing compounds other than the compounds shown in Table 1 may be easily understood by those skilled in the art by referring to the synthesis pathways and raw materials described above.

TABLE 1

Compound	¹ H NMR (CDCl ₃ , 400 MHz)	MS/FAB	
		found	calc.
1	8.46-8.08 (6H, m), 7.81-7.48 (4H, m), 7.38-7.31 (4H, m), 7.13-7.05 (2H, m), 6.88-6.75 (2H, m)	654.1301	654.1303
6	8.08-7.91 (2H, m), 7.81-7.44 (4H, m), 7.37-7.29 (4H, m), 7.14-7.10 (2H, m), 6.40 (2H, s), 2.90 (6H, s), 2.80 (6H, s)	710.1924	710.1929
11	8.56-8.45 (2H, m), 8.35-8.30 (2H, m), 8.11-7.95 (3H, m), 7.82-7.75 (3H, m), 7.38-7.25 (5H, m), 7.15-7.10 (2H, m), 7.01-6.79 (2H, m)	655.1348	665.1351
16	8.57-8.33 (2H, m), 8.09-7.95 (3H, m), 7.80-7.71 (3H, m), 7.39-7.31 (4H, m), 7.15-7.04 (3H, m), 6.40 (3H, s), 2.91 (3H, s), 2.74 (3H, s), 2.45 (3H, s)	707.1815	707.1820
21	8.56-8.55 (1H, m), 8.10-8.08 (2H, m), 7.87-7.70 (5H, m), 7.64-7-14 (10H, m), 6.50-6.46 (1H, m), 3.88 (3H, s)	718.1612	718.1616
26	8.57-8.54 (1H, m), 8.13-8.06 (2H, m), 7.89-7.71 (5H, m), 7.64-7-14 (8H, m), 6.50-6.46 (1H, m), 3.89 (3H, s), 2.21 (3H, s), 1.95 (3H, s)	746.1922	746.1929
31	8.64-8.35 (4H, m), 8.15-8.09 (2H, m), 7.81-7.75 (4H, m), 7.38-7.29 (4H, m), 7.15-7.09 (2H, m), 6.88-6.85 (1H, m)	655.1251	655.1255
36	8.49-8.33 (4H, m), 8.09-8.05 (2H, m), 7.80-7.76 (4H, m), 7.38-7.29 (4H, m), 7.13-7.11 (2H, m), 6.87-6.81 (1H, m)	655.1250	655.1255

Example 1


[0470] As an anode, an ITO glass substrate (having a thickness of 1,200 Å, available from Corning Co., Ltd) was cut to a size of 50 millimeters (mm)×50 mm×0.7 mm,

sonicated in isopropyl alcohol and pure water for 5 minutes in each solvent, cleaned with ultraviolet rays for 30 minutes, and then ozone, and mounted on a vacuum deposition apparatus.



[0471] 2-TNATA was vacuum-deposited on the ITO substrate to form a hole injection layer having a thickness of 600 Å. NPB was vacuum-deposited on the hole injection layer to form a hole transport layer having a thickness of 300 Å.

[0472] BCPDS, POPCPA, and Compound 1 were co-deposited at a ratio of 45:45:10 on the hole transport layer to form an emission layer having a thickness of 300 Å.


[0473] Subsequently, TSPO1 was vacuum-deposited on the emission layer to form a hole blocking layer having a thickness of 50 Å. Alq₃ was vacuum-deposited on the hole blocking layer to form an electron transport layer having a thickness of 300 Å. LiF was deposited on the electron transport layer to form an electron injection layer having a thickness of 10 Å. Al was vacuum-deposited on the electron injection layer to form a cathode having a thickness of 3,000 Å, thereby completing the manufacture of an organic light-emitting device.




-continued




Alq3



BCPDS



POPCPA



TSPO1

Examples 2 to 8 and Comparative Examples 1 to 3


[0474] Additional organic light-emitting devices were manufactured in substantially the same manner as in Example 1, except that the compounds shown in Table 2 were used instead of Compound 1 in the formation of an emission layer.

Evaluation Example

[0475] The driving voltage, current density, luminance, emission color, and emission wavelengths of the organic light-emitting devices manufactured in Examples 1 to 8 and Comparative Examples 1 to 3 were measured using a Keithley SMU 236 and a luminance meter PR650 at a current density of 50 mA/cm². The results thereof are shown in Table 2.


TABLE 2

	Emis- sion layer	Driv- ing vol- tage (V)	Cur- rent den- sity (mA/ cm ²)	Lu- min- ance (cd/m ²)	Cur- rent effi- ciency (cd/A)	Emis- sion color	Emis- sion length (nm)
Example 1	1	5.35	50	4130	8.25	Blue	466
Example 2	6	5.29	51	4230	8.31	Blue	460
Example 3	11	5.41	55	4002	8.05	Blue	475
Example 4	16	5.43	56	4113	8.12	Blue	473
Example 5	21	5.41	49	4222	8.29	Blue	480
Example 6	26	5.39	52	4321	8.44	Blue	477
Example 7	31	5.66	49	4109	8.25	Blue	470
Example 8	36	5.74	47	3988	8.01	Blue	471
Com- para- tive Example 1	A	6.56	50	3870	7.74	Blue	478
Com- para- tive Example 2	B	5.99	49	3850	7.65	Blue	490
Com- para- tive Example 3	C	6.30	48	3650	7.44	Blue	495



1

6




11


16

TABLE 2-continued


Emis- sion layer	Driv- ing vol- tage (V)	Cur- rent density (mA/ cm ²)	Lu- mi- nance (cd/m ²)	Cur- rent effi- ciency (cd/A)	Emis- sion color	Emis- sion wave- length (nm)
------------------------	-------------------------------------	--	---	---	------------------------	--




21




26




31



36




A



B

TABLE 2-continued

Emis- sion layer	Driv- ing vol- tage (V)	Cur- rent density (mA/ cm ²)	Lu- mi- nance (cd/m ²)	Cur- rent effi- ciency (cd/A)	Emis- sion color	Emis- sion wave- length (nm)
------------------------	-------------------------------------	--	---	---	------------------------	--



C

[0476] Referring to the results of Table 2, it was found that the organic light-emitting devices manufactured in Examples 1 to 8 had improved driving voltage, improved luminance, and improved current efficiency, compared with the organic light-emitting devices manufactured in Comparative Examples 1 to 3.

[0477] As is apparent from the foregoing description, an organic light-emitting device including the organometallic compound may have a low driving voltage, excellent luminance, and a high current efficiency.

[0478] As used herein, the terms “use”, “using”, and “used” may be considered synonymous with the terms “utilize”, “utilizing”, and “utilized”, respectively. Further, the use of “may” when describing embodiments of the present disclosure refers to “one or more embodiments of the present disclosure”.

[0479] As used herein, the terms “substantially”, “about”, and similar terms are used as terms of approximation and not as terms of degree, and are intended to account for the inherent deviations in measured or calculated values that would be recognized by those of ordinary skill in the art.


[0480] Also, any numerical range recited herein is intended to include all subranges of the same numerical precision subsumed within the recited range. For example, a range of “1.0 to 10.0” is intended to include all subranges between (and including) the recited minimum value of 1.0 and the recited maximum value of 10.0, that is, having a minimum value equal to or greater than 1.0 and a maximum value equal to or less than 10.0, such as, for example, 2.4 to 7.6. Any maximum numerical limitation recited herein is intended to include all lower numerical limitations subsumed therein and any minimum numerical limitation recited in this specification is intended to include all higher numerical limitations subsumed therein. Accordingly, Applicant reserves the right to amend this specification, including the claims, to expressly recite any sub-range subsumed within the ranges expressly recited herein.

[0481] It should be understood that the embodiments described herein should be considered in a descriptive sense only and not for purposes of limitation. Descriptions of features or aspects within each embodiment should typically be considered as being available for other similar features or aspects in other embodiments.

[0482] While one or more embodiments have been described with reference to the drawings, it will be understood by those of ordinary skill in the art that various changes in form and details may be made therein without departing from the spirit and scope of the disclosure, as defined by the following claims and equivalents thereof.


What is claimed is:

1. An organometallic compound represented by Formula 1:



Formula 1

Formula 1-1



wherein, in Formulae 1 and 1-1,

M_1 is selected from a first-row transition metal, a second-row transition metal, and a third-row transition metal,

L_1 is a ligand represented by Formula 1-1,

L_2 is selected from a monodentate ligand and a bidentate ligand,

n_1 is 1,

n_2 is selected from 0, 1, and 2,

A_{11} to A_{16} are each independently selected from a C_5 - C_{60} carbocyclic group and a C_1 - C_{60} heterocyclic group,

X_{11} to X_{18} are each independently selected from nitrogen (N) and carbon (C),

Y_{11} to Y_{14} are each independently selected from N, C, oxygen (O), and sulfur (S),

i) Z_{11} is boron (B), and Z_{12} is N; or ii) Z_{11} is N, and Z_{12} is B,

T_{11} to T_{14} are each independently selected from a single bond, $*-O-*$, $*-S-*$, $*-N(R_{17})-*$, and $*-C(R_{17})(R_{18})-*$,

L_{11} to L_{13} are each independently selected from a single bond, $*-O-*$, $*-S-*$, $*-C(R_{19})(R_{20})-*$, $*-C(R_{19})=*$, $*=C(R_{19})-*$, $*-C(R_{19})=C(R_{20})-*$, $*-C(=O)-*$, $*-C(=S)-*$, $*-C\equiv C-*$, $*-B(R_{19})-*$, $*-N(R_{19})-*$, $*-P(R_{19})-*$, $*-Si(R_{19})(R_{20})-*$, $*-P(R_{19})(R_{20})-*$, and $*-Ge(R_{19})(R_{20})-*$,

a_{11} to a_{13} are each independently selected from 0, 1, 2, and 3, provided that at least two selected from a_{11} to a_{13} are selected from 1, 2, and 3,

when a_{11} is 0, A_{11} and A_{13} are not linked to each other, when a_{12} is 0, A_{12} and A_{14} are not linked to each other, when a_{13} is 0, A_{11} and A_{12} are not linked to each other,

R_{11} to R_{20} are each independently selected from hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazino group, a hydrazono group, a substituted or unsubstituted C_1 - C_{60} alkyl group, a substituted or unsubstituted C_2 - C_{60} alkenyl group, a substituted or unsubstituted C_2 - C_{60} alkynyl group, a substituted or unsubstituted C_1 - C_{60} alkoxy group, a substituted or unsubstituted C_3 - C_{10} cycloalkyl group, a substituted or unsubstituted C_1 - C_{10} heterocycloalkyl group, a substituted or unsubstituted C_3 - C_{10} cycloalkenyl group, a substituted or unsubstituted C_1 - C_{10} heterocycloalkenyl group, a substituted or unsubstituted C_6 - C_{60} aryl group, a substituted or unsubstituted C_6 - C_{60} aryloxy group, a substituted or unsubstituted C_6 - C_{60} arylthio group, a substituted or unsubstituted C_1 - C_{60} heteroaryl group, a substituted or unsubstituted C_1 - C_{60} heteroaryloxy group, a substituted or unsubstituted C_1 - C_{60} heteroarylthio group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group, —Si(Q_1)(Q_2)(Q_3), —B(Q_1)(Q_2), —N(Q_1)(Q_2), —P(Q_1)(Q_2), —C(=O)(Q_1), —S(=O)(Q_1), —S(=O)₂(Q_1), —P(=O)(Q_1)(Q_2), and —P(=S)(Q_1)(Q_2),

at least two adjacent groups selected from R_{11} to R_{20} are optionally bound to form a substituted or unsubstituted C_5 - C_{60} carbocyclic group or a substituted or unsubstituted C_1 - C_{60} heterocyclic group,

b_{11} to b_{16} are each independently selected from 1, 2, 3, 4, 5, 6, 7, and 8,

wherein Q_1 to Q_3 are each independently selected from hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazino group, a hydrazono group, a C_1 - C_{60} alkyl group, a C_2 - C_{60} alkenyl group, a C_2 - C_{60} alkynyl group, a C_1 - C_{60} alkoxy group, a C_3 - C_{10} cycloalkyl group, a C_1 - C_{10} heterocycloalkyl group, a C_3 - C_{10} cycloalkenyl group, a C_1 - C_{10} heterocycloalkenyl group, a C_6 - C_{60} aryl group, a C_6 - C_{60} aryloxy group, a C_6 - C_{60} arylthio group, a C_1 - C_{60} heteroaryl group, a C_1 - C_{60} heteroaryloxy group, a C_1 - C_{60} heteroarylthio group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, a biphenyl group, and a terphenyl group,

1 to *4 each independently indicate a binding site to M_1 , and
and *1 to *4 each indicate a binding site to an adjacent atom.

2. The organometallic compound of claim 1, wherein M_1 is selected from platinum (Pt), palladium (Pd), copper (Cu), silver (Ag), gold (Au), rhodium (Rh), iridium (Ir), ruthenium (Ru), osmium (Os), titanium (Ti), zirconium (Zr), hafnium (Hf), europium (Eu), terbium (Tb), and thulium (Tm).

3. The organometallic compound of claim 1, wherein A_{11} and A_{12} are each independently selected from a C_5 - C_{60} carbocyclic group and a C_1 - C_{60} heterocyclic group, and A_{13} to A_{16} are each independently selected from a C_5 - C_{60} carbocyclic group.

4. The organometallic compound of claim 1, wherein A_{11} to A_{16} are each independently selected from a benzene group, a naphthalene group, an anthracene group, a phenanthrene group, a phenalene group, a triphenylene group, a pyrene group, a chrysene group, a cyclopentadiene group, a tetrahydronaphthalene group, a furan group, a thiophene

group, a silole group, an indene group, a fluorene group, an indole group, a carbazole group, a benzofuran group, a dibenzofuran group, a benzothiophene group, a dibenzothiophene group, a benzosilole group, a dibenzosilole group, an indenopyridine group, an indolopyridine group, a benzofuroypyridine group, a benzothienopyridine group, a benzosilolopyridine group, an indenopyrimidine group, an indolopyrimidine group, a benzofuroypyrimidine group, a benzothienopyrimidine group, a benzosilolopyrimidine group, a dihydropyridine group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a quinoline group, an isoquinoline group, a quinoxaline group, a quinazoline group, a phenanthroline group, a benzoquinoline group, a benzoisoquinoline group, a benzoquinoxaline group, a benzoquinazoline group, a pyrrole group, a pyrazole group, an imidazole group, a dihydroimidazole group, a triazole group, a dihydrotriazole group, an oxazole group, an iso-oxazole group, a thiazole group, an isothiazole group, an oxadiazole group, a thiadiazole group, a benzopyrazole group, a benzimidazole group, a dihydrobenzimidazole group, an imidazopyridine group, a dihydroimidazopyridine group, an imidazopyrimidine group, a dihydroimidazopyrimidine group, an imidazopyrazine group, a dihydroimidazopyrazine group, a benzoxazole group, a benzothiazole group, a benzoxadiazole group, a benzothiadiazole group, a tetrahydroisoquinoline group, and a tetrahydroquinoline group.

5. The organometallic compound of claim 1, wherein:

A_{11} and A_{12} are each independently selected from an indole group, a carbazole group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a quinoline group, an isoquinoline group, a quinoxaline group, a quinazoline group, a pyrazole group, an imidazole group, a dihydroimidazole group, a triazole group, a dihydrotriazole group, an oxazole group, an iso-oxazole group, a thiazole group, an isothiazole group, an oxadiazole group, a thiadiazole group, a benzopyrazole group, a benzimidazole group, a dihydrobenzimidazole group, a dihydroimidazopyridine group, a dihydroimidazopyrimidine group, a dihydroimidazopyrazine group, a benzoxazole group, and a benzothiazole group, and

A_{13} to A_{16} are each independently selected from a benzene group, a naphthalene group, an indene group, a fluorene group, a benzofuran group, a dibenzofuran group, a benzothiophene group, and a dibenzothiophene group.

6. The organometallic compound of claim 1, wherein A_{13} to A_{16} are each independently a benzene group.

7. The organometallic compound of claim 1, wherein X_{11} to X_{18} are each C.

8. The organometallic compound of claim 1, wherein Y_{11} to Y_{14} are each independently selected from N and C.

9. The organometallic compound of claim 1, wherein T_{11} to T_{14} are each a single bond.

10. The organometallic compound of claim 1, wherein a_{11} and a_{12} are each selected from 1, 2, and 3, and a_3 is 0 or 1.

11. The organometallic compound of claim 1, wherein R_{11} to R_{20} are each independently selected from:

hydrogen, deuterium, —F, —Cl, —Br, —I, a cyano group, a C_1 - C_{20} alkyl group, and a C_1 - C_{20} alkoxy group;

a C_1 - C_{20} alkyl group and a C_1 - C_{20} alkoxy group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, a cyano group, a phenyl group, a biphenyl group, and a terphenyl group;

a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclopentenyl group, a cyclohexenyl group, a phenyl group, a biphenyl group, a terphenyl group, a pentalenyl group, an indenyl group, a naphthyl group, an azulenyl group, an indacenyl group, an acenaphthyl group, a fluorenyl group, a spiro-bifluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenalenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a perylenyl group, a pentacenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, a silolyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an indolyl group, an isoindolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a benzoisoquinolinyl group, a phthalazinyl group, a naphthyridinyl group, a quinoxalinyl group, a benzoquinoxalinyl group, a quinazolinyl group, a benzoquinazolinyl group, a cinnolinyl group, a phenanthridinyl group, an acridinyl group, a phenanthrolinyl group, a phenazinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, a benzosilolyl group, a benzothiazolyl group, a benzoisothiazolyl group, a benzoxazolyl group, a benzoisoxazolyl group, a triazolyl group, a tetrazolyl group, a thiadiazolyl group, an oxadiazolyl group, a triazinyl group, a carbazolyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a dibenzosilolyl group, a benzocarbazolyl group, a naphthobenzofuranyl group, a naphthobenzothiophenyl group, a naphthobenzosilolyl group, a dibenzocarbazolyl group, a dinaphthofuranyl group, a dinaphthothiophenyl group, a dinaphthosilolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, an oxazolopyridinyl group, a thiazolopyridinyl group, a benzonaphthyridinyl group, an azafuorenyl group, an azaspiro-bifluorenyl group, an azacarbazolyl group, an azadibenzofuranyl group, an azadibenzothiophenyl group, an azadibenzosilolyl group, an indenopyrrolyl group, an indolopyrrolyl group, an indenocarbazolyl group, and an indolocarbazolyl group;

a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclopentenyl group, a cyclohexenyl group, a phenyl group, a biphenyl group, a terphenyl group, a pentalenyl group, an indenyl group, a naphthyl group, an azulenyl group, an indacenyl group, an acenaphthyl group, a fluorenyl group, a spiro-bifluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenalenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a perylenyl group, a pentacenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, a silolyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an indolyl group, an isoindolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a benzoisoquinolinyl group, a phthalazinyl group, a naphthyridinyl group, a quinoxalinyl group, a benzoquinoxalinyl group, a quinazolinyl group, a benzoquinazolinyl group, a cinnolinyl group, a phenanthridinyl group, an acridinyl group, a phenanthrolinyl


group, a phenazinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, a benzosilolyl group, a benzothiazolyl group, a benzoisothiazolyl group, a benzoxazolyl group, a benzoisoxazolyl group, a triazolyl group, a tetrazolyl group, a thiadiazolyl group, an oxadiazolyl group, a triazinyl group, a carbazolyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a dibenzosilolyl group, a benzocarbazolyl group, a naphthobenzofuranyl group, a naphthobenzothiophenyl group, a naphthobenzosilolyl group, a dibenzocarbazolyl group, a dinaphthofuranyl group, a dinaphthothiophenyl group, a dinaphthosilolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, an oxazolopyridinyl group, a thiazolopyridinyl group, a benzonaphthyridinyl group, an azafuorenyl group, an azaspiro-bifluorenyl group, an azacarbazolyl group, an azadibenzofuranyl group, an azadibenzothiophenyl group, an azadibenzosilolyl group, an indenopyrrolyl group, an indolopyrrolyl group, an indenocarbazolyl group, and an indolocarbazolyl group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, a cyano group, a C₁-C₂₀ alkyl group, a C₁-C₂₀ alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclopentenyl group, a cyclohexenyl group, a phenyl group, a biphenyl group, a terphenyl group, a pentalenyl group, an indenyl group, a naphthyl group, an azulenyl group, an indacenyl group, an acenaphthyl group, a fluorenyl group, a spiro-bifluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenalenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a perylenyl group, a pentacenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, a silolyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an indolyl group, an isoindolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a benzoisoquinolinyl group, a phthalazinyl group, a naphthyridinyl group, a quinoxalinyl group, a benzoquinoxalinyl group, a quinazolinyl group, a benzoquinazolinyl group, a cinnolinyl group, a phenanthridinyl group, an acridinyl group, a phenanthrolinyl group, a phenazinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, a benzosilolyl group, a benzothiazolyl group, a benzoisothiazolyl group, a benzoxazolyl group, a benzoisoxazolyl group, a triazolyl group, a tetrazolyl group, a thiadiazolyl group, an oxadiazolyl group, a triazinyl group, a carbazolyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a dibenzosilolyl group, a benzocarbazolyl group, a naphthobenzofuranyl group, a naphthobenzothiophenyl group, a naphthobenzosilolyl group, a dibenzocarbazolyl group, a dinaphthofuranyl group, a dinaphthothiophenyl group, a dinaphthosilolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, an oxazolopyridinyl group, a thiazolopyridinyl group, a benzonaphthyridinyl group, an azafuorenyl group, an azaspiro-bifluorenyl group, an azacarbazolyl group, an azadibenzofuranyl group, an azadibenzothiophenyl group, an azadibenzosilolyl group, an indenopyrrolyl group, an indolopyrrolyl group, an indenocarbazolyl group, an indolocarbazolyl group, —Si(Q₃₁)(Q₃₂)(Q₃₃), —N(Q₃₁)(Q₃₂), —B(Q₃₁)(Q₃₂), —C(=O)(Q₃₁), —S(=O)(Q₃₁), —S(=O)₂(Q₃₁), —P(=O)(Q₃₁)(Q₃₂), and —P(=S)(Q₃₁)(Q₃₂); and

—Si(Q₁)(Q₂)(Q₃), —N(Q₁)(Q₂), —B(Q₁)(Q₂), —C(=O)(Q₁), —S(=O)(Q₁), —S(=O)₂(Q₁), —P(=O)(Q₁)(Q₂), and —P(=S)(Q₁)(Q₂),


wherein Q₁ to Q₃ and Q₃₁ to Q₃₃ are each independently selected from hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazino group, a hydrazono group, a C₁-C₆₀ alkyl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, a C₁-C₆₀ alkoxy group, a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₁-C₆₀ heteroaryl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, a biphenyl group, and a terphenyl group.

12. The organometallic compound of claim 1, wherein L₁ is represented by one selected from Formulae 1-11 and 1-12:

Formula 1-11




Formula 1-12




wherein, in Formulae 1-11 and 1-12,

1 to *4, A₁₁ to A₁₆, Y₁₁ to Y₁₄, L₁₁, L₁₂, a11, a12, R₁₁ to R₁₆, and b11 to b16 are each the same as in Formula 1-1.

13. The organometallic compound of claim 1, wherein L_1 is represented by one selected from Formulae 1-31 and 1-32:



Formula 1-31




Formula 1-32


wherein, in Formulae 1-31 and 1-32,

1 to *4, A₁₁, A₁₂, Y₁₃, Y₁₄, L₁₁, L₁₂, a₁₁, a₁₂, R₁₁, R₁₂, and b₁₁ to b₁₆ are each the same as in Formula 1-1, and R_{13a}, R_{13b}, R_{14a}, R_{14b}, R_{15a} to R_{15d}, and R_{16a} to R_{16d} are each the same as R₁₃ in Formula 1-1.

14. The organometallic compound of claim 1, wherein L_2 is represented by one selected from Formulae 7-1 to 7-11:




7-1




7-2




7-3




7-4




7-5




7-6




7-7




7-8



7-9



7-10



7-11

wherein, in Formulae 7-1 to 7-11,

A₇₁ and A₇₂ are each independently selected from a C₅-C₂₀ carbocyclic group and a C₁-C₂₀ heterocyclic group,

X₇₁ and X₇₂ are each independently selected from C and N,

X_{73} is N or C(Q_{73}), X_{74} is N or C(Q_{74}), X_{75} is N or C(Q_{75}), X_{76} is N or C(Q_{76}), and X_{77} is N or C(Q_{77}),

X_{78} is O, S, or N(Q_{78}), and X_{79} is O, S, or N(Q_{79}),

Y_{71} and Y_{72} are each independently selected from a single bond, a double bond, a substituted or unsubstituted C_1 - C_5 alkylene group, a substituted or unsubstituted C_2 - C_5 alkenylene group, and a substituted or unsubstituted C_6 - C_{10} arylene group,

Z_{71} and Z_{72} are each independently selected from N, O, N(R_{75}), P(R_{75})(R_{76}), and As(R_{75})(R_{76}),

Z_{73} is selected from phosphorus (P) and arsenic (As),

Z_{74} is selected from CO and C(R_{75})(R_{76}),

R_{71} to R_{80} and Q_{73} to Q_{79} are each independently selected from hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a substituted or unsubstituted C_1 - C_{60} alkyl group, a substituted or unsubstituted C_2 - C_{60} alkenyl group, a substituted or unsubstituted C_2 - C_{60} alkynyl group, a substituted or unsubstituted C_1 - C_{60} alkoxy group, a substituted or unsubstituted C_3 - C_{10} cycloalkyl group, a substituted or unsubstituted C_1 - C_{10} heterocycloalkyl group, a substituted or unsubstituted C_3 - C_{10} cycloalkenyl group, a substituted or unsubstituted C_1 - C_{10} heterocycloalkenyl group, a substituted or unsubstituted C_6 - C_{60} aryl group, a substituted or unsubstituted C_6 - C_{60} aryloxy group, a substituted or unsubstituted C_6 - C_{60} arylthio group, a substituted or unsubstituted C_1 - C_{60} heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, and a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group, wherein R_{71} and R_{72} are optionally bound to form a ring, R_{77} and R_{78} are optionally bound to form a ring, R_{78} and R_{79} are optionally bound to form a ring, and R_{79} and R_{80} are optionally bound to form a ring,






b71 and b72 are each independently selected from 1, 2, and 3, and

and *1 each indicate a binding site to an adjacent atom.

15. The organometallic compound of claim 1, wherein M_1 is selected from Pt and Pd, n_1 is 1, and n_2 is 0.

16. The organometallic compound of claim 1, wherein the organometallic compound represented by Formula 1 is selected from Compounds 1 to 240:

-continued



2


3

4


1

5


-continued




6



7




8




9


-continued




10



11







12




13

-continued




-continued

14




18

15




19

16







20

17




21

-continued




-continued

22




26

23




27

24







28

25




29

-continued




-continued

30




34

31




35

32







36

33




37

-continued




-continued

38




42

39




43

40




44

41



45


-continued



46


-continued

50




47


51




48





52




49



53



-continued




54

-continued

55

56

57




58

59

60


61

-continued




62


-continued




66




63




67




64



68




65




69


-continued




78



79




80




81


-continued




82



83




84




85

-continued




86

-continued




90

87




91




92



88







93



89




-continued




-continued

94




95



98


99

96







100

97




101

-continued




-continued

102




106

103




107

104







108

105




109

-continued




-continued

110




114

111




115

112







116

113




117

-continued




-continued

118




122

119




123

120







124

121




125

-continued




-continued

126




130

127




131

128







132

129




133

-continued




-continued

134




138

135




139

136







140

137




141

-continued




-continued

142




146

143




147

144




148

145




149

-continued




150


-continued




154




151




155




152



156







153




157

-continued




-continued

158




162

159




163

160




164

161




165

-continued




166

-continued




170


167




171




168




172







169







173



-continued



-continued



174

178

175

179


176

180

177


181

-continued




182


-continued




186




183




187




184



188




185




189


-continued




190



191




192




193


-continued




194



195




196




197


-continued




198



199




200




201


-continued




202



203




204




205

-continued




206

-continued




210

207





211





212

208




213


209




-continued




214



215




216




217


-continued




218



219




220




221

-continued




222


-continued




226




223




227




224



228







225




229

-continued




-continued

230




234

231




235

232




236

233




237

-continued



238


-continued



240

wherein in Compounds 1 to 240, "Ph" represents a phenyl group.

239



17. The organometallic compound of claim 1, wherein the organometallic compound is to emit blue light having a maximum emission wavelength of about 450 nanometers (nm) or greater and less than about 490 nm.

18. An organic light-emitting device comprising: a first electrode; a second electrode; and an organic layer between the first electrode and the second electrode and comprising an emission layer, wherein the organic layer comprises the organometallic compound of claim 1.

19. The organic light-emitting device of claim 18, wherein:

the first electrode is an anode,

the second electrode is a cathode,

the organic layer comprises a hole transport region between the first electrode and the emission layer and/or an electron transport region between the emission layer and the second electrode,

wherein the hole transport region comprises a hole injection layer, a hole transport layer, an emission auxiliary layer, an electron blocking layer, or a combination thereof, and

the electron transport region comprises a hole blocking layer, an electron transport layer, an electron injection layer, or a combination thereof.

20. The organic light-emitting device of claim 18, wherein the emission layer comprises the organometallic compound.

* * * * *

专利名称(译)	有机金属化合物和包括该有机金属化合物的有机发光器件		
公开(公告)号	US20200168798A1	公开(公告)日	2020-05-28
申请号	US16/532426	申请日	2019-08-05
[标]申请(专利权)人(译)	三星显示有限公司		
申请(专利权)人(译)	三星DISPLAY CO. , LTD.		
当前申请(专利权)人(译)	三星DISPLAY CO. , LTD.		
[标]发明人	HAN JUNGHOON KO SOOBYUNG KIM SUNGBUM SHIN SUJIN LEE JAESUNG JEON MINA KIM YOUNGKOOK		
发明人	HAN, JUNGHOON KO, SOOBYUNG KIM, SUNGBUM SHIN, SUJIN AHN, EUNSOO LEE, JAESUNG JEON, MINA KIM, YOUNGKOOK		
IPC分类号	H01L51/00 C09K11/06 C07F15/00		
CPC分类号	H01L51/5096 H01L51/0087 H01L51/5012 C09K2211/1029 C07F15/0086 H01L51/5072 C09K2211/1044 C09K11/06 H01L51/009 H01L51/5092 H01L51/5056 H01L51/5088 C09K2211/1059 H01L51/5016 H01L51/008 C09K2211/185 C07F15/006 H01L51/0084		
优先权	1020180146771 2018-11-23 KR		
外部链接	Espacenet USPTO		

摘要(译)

有机发光器件包括由M1 (L1) n1 (L2) n2 表示的有机金属化合物，其中L1 是由式1-1表示的配体：在式1-1中，* 1至* 4表示与M1的结合位点，并且Z11 和Z12 分别为硼 (B) 和氮 (N) 或N和B。1 结合至B或N原子的α-位置，可以改善配合物中的金属-配体电荷转移。包括有机金属化合物的OLED可以具有长的寿命并且改善的发光效率和比色纯度。

